var title_f2_4_2112="Framingham risk score men";
var content_f2_4_2112=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F67655%7ECARD%2F82417&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F67655%7ECARD%2F82417&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Framingham risk score for men*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"3\" rowspan=\"1\">",
"        Age",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"3\" rowspan=\"1\">",
"        Diabetes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Years",
"       </td>",
"       <td class=\"subtitle2\" colspan=\"2\" rowspan=\"1\">",
"        Points",
"       </td>",
"       <td class=\"subtitle2\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle2\" colspan=\"2\" rowspan=\"1\">",
"        Points&nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\">",
"        30-34",
"       </td>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        -1",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\">",
"        35-39",
"       </td>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        0",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\">",
"        40-44",
"       </td>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        1",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"3\" rowspan=\"1\">",
"        Smoker",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\">",
"        45-49",
"       </td>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        2",
"       </td>",
"       <td class=\"subtitle2\">",
"        &nbsp;&nbsp;",
"       </td>",
"       <td class=\"subtitle2\" colspan=\"2\" rowspan=\"1\">",
"        Points",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\">",
"        50-54",
"       </td>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        3",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\">",
"        55-59",
"       </td>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        4",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\">",
"        60-64",
"       </td>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        5",
"       </td>",
"       <td colspan=\"3\" rowspan=\"3\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\">",
"        65-69",
"       </td>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\">",
"        70-74",
"       </td>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"3\" rowspan=\"1\">",
"        LDL-C",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"3\" rowspan=\"1\">",
"        HDL-C",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        mg/dL",
"       </td>",
"       <td class=\"subtitle2\" colspan=\"1\">",
"        mmol/L",
"       </td>",
"       <td class=\"subtitle2\">",
"        Points",
"       </td>",
"       <td class=\"subtitle2\">",
"        mg/dL",
"       </td>",
"       <td class=\"subtitle2\">",
"        mmol/L",
"       </td>",
"       <td class=\"subtitle2\">",
"        Points",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &lt;100",
"       </td>",
"       <td>",
"        &lt;2.59",
"       </td>",
"       <td>",
"        -3",
"       </td>",
"       <td>",
"        &lt;35",
"       </td>",
"       <td>",
"        &lt;0.90",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        100-129",
"       </td>",
"       <td colspan=\"1\">",
"        2.60-3.36",
"       </td>",
"       <td colspan=\"1\">",
"        0",
"       </td>",
"       <td colspan=\"1\">",
"        35-44",
"       </td>",
"       <td>",
"        0.91-1.16",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        130-159",
"       </td>",
"       <td colspan=\"1\">",
"        3.37-4.14",
"       </td>",
"       <td colspan=\"1\">",
"        0",
"       </td>",
"       <td colspan=\"1\">",
"        45-49",
"       </td>",
"       <td>",
"        1.17-1.29",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        160-190",
"       </td>",
"       <td colspan=\"1\">",
"        4.50-4.92",
"       </td>",
"       <td colspan=\"1\">",
"        1",
"       </td>",
"       <td colspan=\"1\">",
"        50-54",
"       </td>",
"       <td>",
"        1.30-1.55",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &gt;190",
"       </td>",
"       <td>",
"        &gt;4.92",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        &gt;60",
"       </td>",
"       <td>",
"        &gt;1.56",
"       </td>",
"       <td>",
"        -1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Systolic blood pressure, mmHg",
"       </td>",
"       <td class=\"subtitle1\">",
"        Diastolic &lt;80 mmHg",
"       </td>",
"       <td class=\"subtitle1\">",
"        Diastolic 80-84",
"       </td>",
"       <td class=\"subtitle1\">",
"        Diastolic 85-89",
"       </td>",
"       <td class=\"subtitle1\">",
"        Diastolic 90-99",
"       </td>",
"       <td class=\"subtitle1\">",
"        Diastolic &ge;100",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &lt;120",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        120-129",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        130-139",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        140-159",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &ge;160",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"6\" rowspan=\"1\">",
"        Coronary",
"heart disease (CHD) risk",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Total points",
"       </td>",
"       <td class=\"subtitle2\" colspan=\"2\" rowspan=\"1\">",
"        10 yr CHD risk, percent",
"       </td>",
"       <td class=\"subtitle2\">",
"        Total points",
"       </td>",
"       <td class=\"subtitle2\" colspan=\"2\" rowspan=\"1\">",
"        10 yr CHD risk, percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &lt;-3",
"       </td>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        1",
"       </td>",
"       <td>",
"        6",
"       </td>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        11",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        -2",
"       </td>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        2",
"       </td>",
"       <td>",
"        7",
"       </td>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        14",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        -1",
"       </td>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        2",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        18",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        0",
"       </td>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        3",
"       </td>",
"       <td>",
"        9",
"       </td>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        22",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1",
"       </td>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        4",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        27",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2",
"       </td>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        5",
"       </td>",
"       <td>",
"        11",
"       </td>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        33",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3",
"       </td>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        6",
"       </td>",
"       <td>",
"        12",
"       </td>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        40",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4",
"       </td>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        7",
"       </td>",
"       <td>",
"        13",
"       </td>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        47",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5",
"       </td>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        9",
"       </td>",
"       <td>",
"        14",
"       </td>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        56",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Framingham risk scoring system for men. Use to calculate the risk of developing clinical coronary heart disease (CHD) in men who do not have known CHD. Clinical CHD includes angina pectoris, recognized or unrecognized myocardial infarction (MI), coronary insufficiency (prolonged chest discomfort associated with transient repolarization abnormalities without criteria for MI), or CHD death.",
"     <br>",
"      To calculate the Framingham risk estimate, add points for age, presence of diabetes, smoking status, LDL-cholesterol (LDL-C), HDL-cholesterol (HDL-C), and blood pressure. Find the total point score on the bottom table to determine the 10-year risk of CHD.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Adapted with permission from Wilson PW, D'Agostino R, Levy D, et al. Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97:1837. Copyright &copy; 1998 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Framingham risk score for women*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"3\" rowspan=\"1\">",
"        Age",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"3\" rowspan=\"1\">",
"        Diabetes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Years",
"       </td>",
"       <td class=\"subtitle2\" colspan=\"2\" rowspan=\"1\">",
"        Points",
"       </td>",
"       <td class=\"subtitle2 subtitle2\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle2\" colspan=\"2\">",
"        Points",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\">",
"        30-34",
"       </td>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        -9",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td colspan=\"2\">",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\">",
"        35-39",
"       </td>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        -4",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td colspan=\"2\">",
"        4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\">",
"        40-44",
"       </td>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        0",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"3\" rowspan=\"1\">",
"        Smoker",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\">",
"        45-49",
"       </td>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        3",
"       </td>",
"       <td class=\"subtitle2\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle2\" colspan=\"2\">",
"        Points",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\">",
"        50-54",
"       </td>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        6",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td colspan=\"2\">",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\">",
"        55-59",
"       </td>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        7",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td colspan=\"2\">",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\">",
"        60-64",
"       </td>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        8",
"       </td>",
"       <td colspan=\"3\" rowspan=\"3\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\">",
"        65-69",
"       </td>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\">",
"        70-74",
"       </td>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"3\" rowspan=\"1\">",
"        LDL-C",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"3\" rowspan=\"1\">",
"        HDL-C",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        mg/dL",
"       </td>",
"       <td class=\"subtitle2\" colspan=\"1\">",
"        mmol/L",
"       </td>",
"       <td class=\"subtitle2\">",
"        Points",
"       </td>",
"       <td class=\"subtitle2\">",
"        mg/dL",
"       </td>",
"       <td class=\"subtitle2\">",
"        mmol/L",
"       </td>",
"       <td class=\"subtitle2\">",
"        Points",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &lt;100",
"       </td>",
"       <td>",
"        &lt;2.59",
"       </td>",
"       <td>",
"        -2",
"       </td>",
"       <td>",
"        &lt;35",
"       </td>",
"       <td>",
"        &lt;0.90",
"       </td>",
"       <td>",
"        <span style=\"font-weight: bold;\">",
"         5",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        100-129",
"       </td>",
"       <td colspan=\"1\">",
"        2.60-3.36",
"       </td>",
"       <td colspan=\"1\">",
"        0",
"       </td>",
"       <td colspan=\"1\">",
"        35-44",
"       </td>",
"       <td>",
"        0.91-1.16",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        130-159",
"       </td>",
"       <td colspan=\"1\">",
"        3.37-4.14",
"       </td>",
"       <td colspan=\"1\">",
"        0",
"       </td>",
"       <td colspan=\"1\">",
"        45-49",
"       </td>",
"       <td>",
"        1.17-1.29",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        160-190",
"       </td>",
"       <td colspan=\"1\">",
"        4.50-4.92",
"       </td>",
"       <td colspan=\"1\">",
"        2",
"       </td>",
"       <td colspan=\"1\">",
"        50-54",
"       </td>",
"       <td>",
"        1.30-1.55",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &gt;190",
"       </td>",
"       <td>",
"        &gt;4.92",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        &gt;60",
"       </td>",
"       <td>",
"        &gt;1.56",
"       </td>",
"       <td>",
"        -2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Systolic blood pressure, mmHg",
"       </td>",
"       <td class=\"subtitle1\">",
"        Diastolic &lt;80 mmHg",
"       </td>",
"       <td class=\"subtitle1\">",
"        Diastolic 80-84",
"       </td>",
"       <td class=\"subtitle1\">",
"        Diastolic 85-89",
"       </td>",
"       <td class=\"subtitle1\">",
"        Diastolic 90-99",
"       </td>",
"       <td class=\"subtitle1\">",
"        Diastolic &ge;100",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &lt;120",
"       </td>",
"       <td>",
"        -3",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        120-129",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        130-139",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        140-159",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &ge;160",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"6\" rowspan=\"1\">",
"        Coronary",
"heart disease (CHD) risk",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Total points",
"       </td>",
"       <td class=\"subtitle2\" colspan=\"2\">",
"        10 yr CHD risk, percent",
"       </td>",
"       <td class=\"subtitle2\">",
"        Total points",
"       </td>",
"       <td class=\"subtitle2\" colspan=\"2\" rowspan=\"1\">",
"        10 yr CHD risk, percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &lt;-2",
"       </td>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        1",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        -1",
"       </td>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        2",
"       </td>",
"       <td>",
"        9",
"       </td>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        9",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        0",
"       </td>",
"       <td colspan=\"2\">",
"        2",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        11",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1",
"       </td>",
"       <td colspan=\"2\">",
"        2",
"       </td>",
"       <td>",
"        11",
"       </td>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        13",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2",
"       </td>",
"       <td colspan=\"2\">",
"        3",
"       </td>",
"       <td>",
"        12",
"       </td>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        15",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3",
"       </td>",
"       <td colspan=\"2\">",
"        3",
"       </td>",
"       <td>",
"        13",
"       </td>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        17",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4",
"       </td>",
"       <td colspan=\"2\">",
"        4",
"       </td>",
"       <td>",
"        14",
"       </td>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        20",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5",
"       </td>",
"       <td colspan=\"2\">",
"        5",
"       </td>",
"       <td>",
"        15",
"       </td>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        24",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        6",
"       </td>",
"       <td colspan=\"2\">",
"        6",
"       </td>",
"       <td>",
"        16",
"       </td>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        27",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        7",
"       </td>",
"       <td colspan=\"2\">",
"        7",
"       </td>",
"       <td>",
"        17",
"       </td>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        32",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Framingham risk scoring system for women. Use to calculate the risk of developing clinical coronary heart disease (CHD) in women who do not have known CHD. Clinical CHD includes angina pectoris, recognized or unrecognized myocardial infarction (MI), coronary insufficiency (prolonged chest discomfort associated with transient repolarization abnormalities without criteria for MI), or CHD death.",
"     <br>",
"      To calculate the Framingham risk estimate, add points for age, presence of diabetes, smoking status, LDL-cholesterol (LDL-C), HDL-cholesterol (HDL-C), and blood pressure. Find the total point score on the bottom table to determine the 10-year risk of CHD.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Adapted with permission from Wilson PW, D'Agostino R, Levy D, et al. Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97:1837. Copyright &copy; 1998 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_4_2112=[""].join("\n");
var outline_f2_4_2112=null;
var title_f2_4_2113="Closure rectovaginal fistula";
var content_f2_4_2113=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F52097&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F52097&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Repair of a small rectovaginal fistula through a transvaginal approach",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 406px; height: 415px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The rectal mucosa is closed using a running delayed absorbable suture. Note that the suture line is begun at least 5 mm above the apex of the fistula.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_4_2113=[""].join("\n");
var outline_f2_4_2113=null;
var title_f2_4_2114="Interactive diabetes case 7: Management of diabetes in a 72-year-old man with type 2 diabetes, GI bleeding and multiple other medical problems";
var content_f2_4_2114=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"11\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Interactive diabetes case 7: Management of diabetes in a 72-year-old man with type 2 diabetes, GI bleeding and multiple other medical problems",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/4/2114/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/4/2114/contributors\">",
"     Lloyd Axelrod, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/4/2114/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/4/2114/contributors\">",
"     David M Nathan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/4/2114/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/4/2114/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?2/4/2114/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     CASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 72-year-old man returns to see you in your office following a recent hospital admission for GI bleeding. The patient is treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    for cardiac indications. He has had recurrent GI bleeding requiring intermittent blood transfusions for approximately six months. The site of the bleeding has eluded diagnosis despite upper GI endoscopy, colonoscopy, and capsule enteroscopy. The patient has had type 2 diabetes for 23 years, and has been on insulin for 11 years. His diabetes is complicated by retinopathy, peripheral neuropathy, and renal insufficiency. The patient has rheumatic heart disease, coronary artery disease, congestive heart failure, and atrial fibrillation. He has had mitral and aortic valve replacements and recent placement of a stent in the left anterior descending artery. The estimated left ventricular ejection fraction is 26 percent. On the day of discharge from the hospital, the BUN was 66",
"    <span class=\"nowrap\">",
"     mg/dL,",
"    </span>",
"    creatinine 2.2",
"    <span class=\"nowrap\">",
"     mg/dL,",
"    </span>",
"    international normalized ratio (INR) 2.4, and hemoglobin A1c (HbA1c) 5.40 percent. His medications include NPH insulin 58 units every morning and 24 units every day at bedtime. He is also on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/52/28488?source=see_link\">",
"     furosemide",
"    </a>",
"    120 mg twice a day,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/57/34711?source=see_link\">",
"     potassium chloride",
"    </a>",
"    20 mEq twice a day,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/22/17767?source=see_link\">",
"     spironolactone",
"    </a>",
"    50 mg once a day,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/32/1542?source=see_link\">",
"     metolazone",
"    </a>",
"    5 mg every other day,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/39/15993?source=see_link\">",
"     esomeprazole",
"    </a>",
"    40 mg a day, warfarin 4 mg a day, and clopidogrel 75 mg a day. He has been eating regularly and checking his blood glucose level at home since discharge. The glucose values before breakfast have been 131 to 152 mg",
"    <span class=\"nowrap\">",
"     /dL",
"    </span>",
"    (7.3 to 8.4",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    and those before supper have been 143 to 197",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (7.9 to 10.9",
"    <span class=\"nowrap\">",
"     mmol/L).",
"    </span>",
"   </p>",
"   <p>",
"    How",
"    would you manage the patient's diabetes at this time?",
"   </p>",
"   <p>",
"    A1 - Reduce insulin doses by 50 percent because the HbA1c indicates excessively tight control in this patient in whom hypoglycemia is of more than the usual concern because of his cardiovascular disease. (See",
"    <a class=\"medical medical_answer\" href=\"./interactive-diabetes-case-7-management-of-diabetes-in-a-72-year-old-man-with-type-2-diabetes-and-multiple-medical-problems-a1?source=see_link\">",
"     \"Interactive diabetes case 7: Management of diabetes in a 72-year-old man with type 2 diabetes and multiple medical problems - A1\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A2 - Stop insulin to avert hypoglycemia in this patient in whom hypoglycemia is of more than the usual concern because of his cardiovascular disease and begin",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/6/29800?source=see_link\">",
"     glyburide",
"    </a>",
"    10 mg before breakfast and 10 mg before supper to provide more gentle control of the diabetes. (See",
"    <a class=\"medical medical_answer\" href=\"./interactive-diabetes-case-7-management-of-diabetes-in-a-72-year-old-man-with-type-2-diabetes-and-multiple-medical-problems-a2?source=see_link\">",
"     \"Interactive diabetes case 7: Management of diabetes in a 72-year-old man with type 2 diabetes and multiple medical problems - A2\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A3 - Stop insulin to avert hypoglycemia in this patient in whom hypoglycemia is of more than the usual concern because of his cardiovascular disease and begin",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    1000 mg before breakfast and supper to control diabetes without the risk of hypoglycemia. (See",
"    <a class=\"medical medical_answer\" href=\"./interactive-diabetes-case-7-management-of-diabetes-in-a-72-year-old-man-with-type-2-diabetes-and-multiple-medical-problems-a3?source=see_link\">",
"     \"Interactive diabetes case 7: Management of diabetes in a 72-year-old man with type 2 diabetes and multiple medical problems - A3\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A4 - Increase the dose of NPH insulin before breakfast to 64 units to control the hyperglycemia before supper, increase the dose of NPH insulin at bedtime to 28 units to control the hyperglycemia before breakfast and ignore the HbA1c level. (See",
"    <a class=\"medical medical_answer\" href=\"./interactive-diabetes-case-7-management-of-diabetes-in-a-72-year-old-man-with-type-2-diabetes-and-multiple-medical-problems-a4?source=see_link\">",
"     \"Interactive diabetes case 7: Management of diabetes in a 72-year-old man with type 2 diabetes and multiple medical problems - A4\"",
"    </a>",
"    .)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4104 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-1F43DE5731-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_4_2114=[""].join("\n");
var outline_f2_4_2114=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      CASE",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_answer\" href=\"./interactive-diabetes-case-7-management-of-diabetes-in-a-72-year-old-man-with-type-2-diabetes-and-multiple-medical-problems-a1?source=related_link\">",
"      Interactive diabetes case 7: Management of diabetes in a 72-year-old man with type 2 diabetes and multiple medical problems - A1",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_answer\" href=\"./interactive-diabetes-case-7-management-of-diabetes-in-a-72-year-old-man-with-type-2-diabetes-and-multiple-medical-problems-a2?source=related_link\">",
"      Interactive diabetes case 7: Management of diabetes in a 72-year-old man with type 2 diabetes and multiple medical problems - A2",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_answer\" href=\"./interactive-diabetes-case-7-management-of-diabetes-in-a-72-year-old-man-with-type-2-diabetes-and-multiple-medical-problems-a3?source=related_link\">",
"      Interactive diabetes case 7: Management of diabetes in a 72-year-old man with type 2 diabetes and multiple medical problems - A3",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_answer\" href=\"./interactive-diabetes-case-7-management-of-diabetes-in-a-72-year-old-man-with-type-2-diabetes-and-multiple-medical-problems-a4?source=related_link\">",
"      Interactive diabetes case 7: Management of diabetes in a 72-year-old man with type 2 diabetes and multiple medical problems - A4",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_4_2115="Localized granuloma annulare on hands";
var content_f2_4_2115=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F73823&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F73823&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 596px\">",
"   <div class=\"ttl\">",
"    Localized granuloma annulare",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 576px; height: 227px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A 66-year-old woman presents with slowly enlarging plaques on the backs of the hands. The largest lesions have been present for six years while the smaller, more proximal 2 cm diameter annular lesions appeared within the past year. All lesions show persistent blanching erythema in central areas.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_4_2115=[""].join("\n");
var outline_f2_4_2115=null;
var title_f2_4_2116="T2 esophageal cancer EUS";
var content_f2_4_2116=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F72321&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F72321&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    T2 esophageal cancer",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 463px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Endoscopic ultrasound image showing stage T2 esophageal cancer.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of John R Saltzman, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_4_2116=[""].join("\n");
var outline_f2_4_2116=null;
var title_f2_4_2117="Guaifenesin, pseudoephedrine, and dextromethorphan: Drug information";
var content_f2_4_2117=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Guaifenesin, pseudoephedrine, and dextromethorphan: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?5/15/5365?source=see_link\">",
"    see \"Guaifenesin, pseudoephedrine, and dextromethorphan: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F178056\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Ambifed DM;",
"     </li>",
"     <li>",
"      Ambifed-G DM;",
"     </li>",
"     <li>",
"      ExeFen-DMX;",
"     </li>",
"     <li>",
"      Maxifed DM [DSC];",
"     </li>",
"     <li>",
"      Maxifed DMX",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F178057\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Balminil DM + Decongestant + Expectorant;",
"     </li>",
"     <li>",
"      Benylin&reg; DM-D-E",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F178072\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antitussive/Decongestant/Expectorant",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F178060\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Expectorant/decongestant/cough suppressant:",
"     </b>",
"     Oral:",
"     <b>",
"      Note:",
"     </b>",
"     Also refer to specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Liquid (OTC labeling; Maxifed DM): 5 mL every 4-6 hours, not to exceed 30 mL/24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Tablet (OTC labeling; Ambifed-G DM, Maxifed DM): One tablet every 4-6 hours, not to exceed 6 tablets/24 hours",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F178067\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Expectorant/decongestant/cough suppressant:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Note:",
"     </b>",
"     Also refer to specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Liquid (OTC labeling; Maxifed DM):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Children 6-11 years: 2.5 mL every 4-6 hours, not to exceed 15 mL/24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &ge;12 years: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Tablet (OTC labeling; Ambifed-G DM, Maxifed DM):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Children 6-11 years  One-half tablet every 4-6 hours, not to exceed 3 tablets/24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &ge;12 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F178061\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F178046\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Liquid, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Maxifed DM: Guaifenesin 200 mg, pseudoephedrine hydrochloride 20 mg, and dextromethorphan hydrobromide 10 mg per 5 mL (473 mL) [sugar free, contains ethanol 0.1%, propylene glycol; orange cream flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ambifed DM: Guaifenesin 400 mg, pseudoephedrine hydrochloride 30 mg, and dextromethorphan hydrobromide 20 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ambifed-G DM: Guaifenesin 400 mg, pseudoephedrine hydrochloride 20 mg, and dextromethorphan hydrobromide 20 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     ExeFen-DMX:  Guaifenesin 400 mg, pseudoephedrine hydrochloride 60 mg, and dextromethorphan hydrobromide 20 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Maxifed DM: Guaifenesin 400 mg, pseudoephedrine hydrochloride 40 mg, and dextromethorphan hydrobromide 20 mg [DSC]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Maxifed DMX: Guaifenesin 400 mg, pseudoephedrine hydrochloride 60 mg, and dextromethorphan hydrobromide 20 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F178035\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F178048\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Long-acting formulations should not be crushed or chewed. Take with a full glass of water.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F178047\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Temporarily relieves nasal congestion and controls cough due to minor throat and bronchial irritation; helps loosen phlegm and thin bronchial secretions to make coughs more productive",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F178070\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F178051\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to guaifenesin, pseudoephedrine, sympathomimetic amines, dextromethorphan, or any component of the formulation; use with or within 14 days of MAO inhibitors; severe hypertension or cardiovascular disease",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F178039\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with cardiovascular disease (including hypertension and ischemic heart disease); contraindicated with severe disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use with caution in patients with diabetes mellitus.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Increased intraocular pressure/glaucoma: Use with caution in patients with increased intraocular pressure or glaucoma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Prostatic hyperplasia/urinary obstruction: Use with caution in patients with prostatic hyperplasia and/or GU obstruction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thyroid dysfunction: Use with caution in patients with thyroid dysfunction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Debilitated patients: Use with caution in debilitated, sedated and/or patients confined to the supine position.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in the elderly; may be more sensitive to adverse effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Use with caution in atopic children. Not for OTC use in children &lt;6 years of age.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cough: Appropriate use: Underlying cause of cough should be determined prior to prescribing.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F178068\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F178043\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abiraterone Acetate: May increase the serum concentration of CYP2D6 Substrates. Management: Avoid concurrent use of abiraterone with CYP2D6 substrates that have a narrow therapeutic index whenever possible.  When concurrent use is not avoidable, monitor patients closely for signs/symptoms of toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Blockers: May diminish the hypertensive effect of Alpha-/Beta-Agonists. Similarly, Alpha-/Beta-Agonists may antagonize hypotensive effects of Alpha1-Blockers. Alpha1-Blockers may diminish the vasoconstricting effect of Alpha-/Beta-Agonists. Similarly, Alpha-/Beta-Agonists may antagonize Alpha1-Blocker vasodilation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the excretion of Alpha-/Beta-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Aluminum Hydroxide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotics: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtoMOXetine: May enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzylpenicilloyl Polylysine: Alpha-/Beta-Agonists may diminish the diagnostic effect of Benzylpenicilloyl Polylysine.  Management: Consider use of a histamine skin test as a positive control to assess a patient's ability to mount a wheal and flare response.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bromocriptine: Alpha-/Beta-Agonists may enhance the adverse/toxic effect of Bromocriptine. Including increased blood pressure, ventricular arrhythmias, and seizure.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cannabinoids: May enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Carbonic Anhydrase Inhibitors: May decrease the excretion of Alpha-/Beta-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Brinzolamide; Dorzolamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Moderate): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Strong): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Darunavir: May increase the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergot Derivatives: May enhance the hypertensive effect of Alpha-/Beta-Agonists. Ergot Derivatives may enhance the vasoconstricting effect of Alpha-/Beta-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Ergoloid Mesylates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     FentaNYL: Alpha-/Beta-Agonists (Indirect-Acting) may decrease the serum concentration of FentaNYL. Specifically, fentanyl nasal spray serum concentrations may decrease and onset of effect may be delayed.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iobenguane I 123: Sympathomimetics may diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the serotonergic effect of Dextromethorphan. This may cause serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the hypertensive effect of Alpha-/Beta-Agonists (Indirect-Acting).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: Serotonin Modulators may enhance the adverse/toxic effect of Metoclopramide. This may be manifest as symptoms consistent with serotonin syndrome or neuroleptic malignant syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: May increase the serum concentration of Dextromethorphan. Management: Avoid concurrent use of these agents when possible, unless the increased psychoactive effects of dextromethorphan are desired.  Since codeine activation is also inhibited by quinidine, codeine is unlikely to be suitable as an alternative antitussive.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May enhance the serotonergic effect of Dextromethorphan. Selective Serotonin Reuptake Inhibitors may increase the serum concentration of Dextromethorphan. Management: Avoid the concurrent use of dextromethorphan and SSRIs, particularly fluoxetine and paroxetine, when possible.  The risk for this interaction may persist for several weeks following discontinuation of fluoxetine or paroxetine.",
"     <b>",
"      Exceptions:",
"     </b>",
"     FluvoxaMINE.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin Modulators: May enhance the adverse/toxic effect of other Serotonin Modulators. The development of serotonin syndrome may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin/Norepinephrine Reuptake Inhibitors: May enhance the tachycardic effect of Alpha-/Beta-Agonists. Serotonin/Norepinephrine Reuptake Inhibitors may enhance the vasopressor effect of Alpha-/Beta-Agonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Spironolactone: May diminish the vasoconstricting effect of Alpha-/Beta-Agonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F178052\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F178053\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F9549681\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Some products may contain phenylalanine.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323176\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (Robitussin Cough/Cold D Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     30-15-200 mg/5 mL (237 mL): $8.70",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (Trispec PSE Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     30-15-125 mg/5 mL (120 mL): $13.16",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (Trispec PSE Pediatric Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     30-15-125 mg/5 mL (30 mL): $13.16",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (Tusnel Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     30-15-200 mg/5 mL (473 mL): $26.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (Tusnel Pediatric Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     15-5-50 mg/5 mL (118 mL): $9.60",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (Tusnel-DM Pediatric Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     7.5-2.5-25 mg/mL (60 mL): $12.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (Z-Cof 12DM Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     30-15-175 mg/5 mL (473 mL): $208.53",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (Z-Cof I Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     30-15-211 mg/5 mL (473 mL): $118.75",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Aldex GS DM Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     30-15-190 mg (100): $124.99",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F178054\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Balminil DM + Decongestant + Expectorant (CA);",
"     </li>",
"     <li>",
"      Benylin DM-D-E (CA);",
"     </li>",
"     <li>",
"      DextroPlus (HK);",
"     </li>",
"     <li>",
"      Koffex DM + Decongestant + Expectorant (CA);",
"     </li>",
"     <li>",
"      Novahistex DM Decongestant Expectorant (CA);",
"     </li>",
"     <li>",
"      Novahistine DM Decongestant Expectorant (CA);",
"     </li>",
"     <li>",
"      Robitussin Cough &amp; Cold (CA);",
"     </li>",
"     <li>",
"      Thymicol (KR)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F178038\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F178050\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8966 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-79.122.249.114-3C057D9C1B-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_4_2117=[""].join("\n");
var outline_f2_4_2117=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178056\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178057\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178072\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178060\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178067\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178061\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178046\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178035\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178048\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178047\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178070\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178051\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178039\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178068\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178043\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178052\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178053\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9549681\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323176\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178054\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178038\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178050\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8966\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8966|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?5/15/5365?source=related_link\">",
"      Guaifenesin, pseudoephedrine, and dextromethorphan: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_4_2118="Sarcoidosis stage II PA";
var content_f2_4_2118=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F78632&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F78632&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Sarcoidosis, stage 2",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 340px; height: 346px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Chest radiograph. Bilateral enlarged hilar lymph nodes as well as right paratracheal and aortopulmonary lymph nodes are visible. Fine linear and reticular opacities are present in the perihilar lung parenchyma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal chest radiograph",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 371px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Posteroanterior view of a normal chest radiograph.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Carol M Black, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_4_2118=[""].join("\n");
var outline_f2_4_2118=null;
var title_f2_4_2119="CBD obstruction OLT";
var content_f2_4_2119=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F50820%7EGAST%2F63968%7EGAST%2F58463&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F50820%7EGAST%2F63968%7EGAST%2F58463&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Common bile duct obstruction following liver transplantation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 293px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Endoscopic retrograde cholangiopancreatography in a patient with jaundice after liver transplantation demonstrates almost complete obstruction of the bile duct anastomosis (large arrow) with minimal passage of contrast throughout the obstruction (small arrows). This lesion was successfully treated with balloon dilation",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jonathan Kruskal, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Anastomotic stricture following balloon dilation in a liver tranplatation recipient",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 292px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A cholangiogram obtained following balloon dilation of an anastomotic stricture in a patient who underwent liver transplantation demonstrates dilated intrahepatic ducts and a residual, but wider, stricture at the anastamosis (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jonathan Kruskal, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 511px\">",
"   <div class=\"ttl\">",
"    Severe anastomotic stricture in the distal biliary tract following liver transplantation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 491px; height: 319px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Endoscopic retrograde cholangiogram (ERC) image of the distal biliary tract in a patient who developed abnormal liver enzymes one month after liver transplantation. Panel A) The ERC shows a severe anastomotic stricture. Panel B) shows a thru-the scope (TTS) balloon being inserted across the stricture to dilate the anastomosis stricture. The stricture was dilated followed by placement of a plastic stent.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Karen Krok, MD and Paul J Thuluvath, MBBS, MD, FRCP.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_4_2119=[""].join("\n");
var outline_f2_4_2119=null;
var title_f2_4_2120="Tumor necrosis factor-alpha inhibitors: Induction of antibodies, autoantibodies, and autoimmune diseases";
var content_f2_4_2120=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Tumor necrosis factor-alpha inhibitors: Induction of antibodies, autoantibodies, and autoimmune diseases",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/4/2120/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/4/2120/contributors\">",
"     John H Stone, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/4/2120/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/4/2120/contributors\">",
"     RN Maini, BA, MB BChir, FRCP, FMedSci, FRS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/4/2120/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/4/2120/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?2/4/2120/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 16, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inhibitors of tumor necrosis factor (TNF)-alpha represent important treatment advances in a number of inflammatory conditions, including rheumatoid arthritis, the seronegative spondyloarthropathies, and inflammatory bowel disease. TNF-alpha inhibitors offer a targeted strategy that contrasts with the nonspecific immunosuppressive agents traditionally used to treat most inflammatory diseases. However, multiple adverse effects of TNF-alpha inhibition have been identified through both clinical trials and post-marketing surveillance. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Injection site reactions",
"     </li>",
"     <li>",
"      Infusion reactions",
"     </li>",
"     <li>",
"      Infections",
"     </li>",
"     <li>",
"      Demyelinating disease",
"     </li>",
"     <li>",
"      Heart failure",
"     </li>",
"     <li>",
"      Malignancy",
"     </li>",
"     <li>",
"      Induction of autoimmunity",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Problems related to antibody formation, to autoantibody formation, and to the development of autoimmune diseases in association with the use of TNF-alpha inhibitors are reviewed here. Other major complications of TNF-alpha therapy such as injection reactions, infusion reactions, tuberculosis, other infections, malignancy, demyelinating disease, and heart failure are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/55/40825?source=see_link\">",
"     \"Tumor necrosis factor-alpha inhibitors: An overview of adverse effects\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/38/24169?source=see_link\">",
"     \"Tumor necrosis factor-alpha inhibitors and mycobacterial infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/49/32538?source=see_link\">",
"     \"Tumor necrosis factor-alpha inhibitors: Risk of bacterial, viral, and fungal infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/53/33624?source=see_link\">",
"     \"Tumor necrosis factor-alpha inhibitors: Risk of malignancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENERAL ISSUES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The adverse effects associated with TNF-alpha inhibitors are potentially serious. However, these risks must be interpreted in the context of the potential benefits and adverse effects associated with conventional therapies (eg, glucocorticoids,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    ). The decision to use an anti-TNF-alpha agent is an individual one, based upon the specific clinical features and the unique risk profile of a given patient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     TNF-alpha antagonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;Five inhibitors of TNF-alpha are approved for the treatment of a variety of inflammatory illnesses (eg, rheumatoid arthritis, Crohn&rsquo;s disease) by the United States Food and Drug Administration (FDA). These medications are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"       Etanercept",
"      </a>",
"      &mdash; Etanercept consists of two p75 TNF-alpha receptors coupled to the constant region of human immunoglobulin G1 (IgG1). Thus, etanercept is a fusion protein.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"       Infliximab",
"      </a>",
"      &mdash; Infliximab is comprised of the human constant region of IgG1 coupled to the variable regions of mouse anti-TNF-alpha. Thus, infliximab is a chimeric",
"      <span class=\"nowrap\">",
"       (mouse/human)",
"      </span>",
"      anti-TNF-alpha antibody.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"       Adalimumab",
"      </a>",
"      &mdash; Adalimumab is a human monoclonal antibody comprised of the human constant region of IgG1 attached to human variable regions. Thus, adalimumab is a fully human monoclonal anti-TNF-alpha antibody.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/6/39014?source=see_link\">",
"       Certolizumab pegol",
"      </a>",
"      &mdash; Certolizumab pegol is an antigen-binding fragment (Fab&rsquo;) of a humanized monoclonal antibody coupled to polyethylene glycol.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/24/35206?source=see_link\">",
"       Golimumab",
"      </a>",
"      &mdash; Golimumab is a human IgG1 kappa monoclonal antibody specific for human TNF-alpha that neutralizes TNF-alpha activity. Golimumab binds to both the soluble and transmembrane bioactive forms of human TNF-alpha.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     Infliximab",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"     adalimumab",
"    </a>",
"    both have a broader clinical spectrum of activity than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    . For example, the former medications are effective in many cases of inflammatory bowel disease (IBD) and sarcoidosis, as well as RA, psoriatic arthritis, and the seronegative spondyloarthropathies [",
"    <a class=\"abstract\" href=\"UTD.htm?2/4/2120/abstract/1\">",
"     1",
"    </a>",
"    ]. In contrast, etanercept does not appear to be effective in IBD or in sarcoidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?2/4/2120/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/6/39014?source=see_link\">",
"     Certolizumab pegol",
"    </a>",
"    received regulatory approval first for use in Crohn&rsquo;s disease and subsequently for rheumatoid arthritis.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/24/35206?source=see_link\">",
"     Golimumab",
"    </a>",
"    has been approved for use in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     NEUTRALIZING ANTIBODIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The formation of neutralizing antibodies is a potential concern with TNF-alpha inhibitors as they may lead to allergic reactions or to loss or lack of efficacy. The risk of developing neutralizing antibodies varies with the type of TNF-alpha inhibitor:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Neutralizing antibodies are a significant concern with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"       infliximab",
"      </a>",
"      because of the chimeric nature of that molecule. Human antichimeric antibodies (HACA) can form against the mouse portions of the molecule.",
"     </li>",
"     <li>",
"      Neutralizing antibodies pose fewer problems with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"       adalimumab",
"      </a>",
"      than",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"       infliximab",
"      </a>",
"      , because the antibody is fully humanized. However, the formation of human antihuman antibodies (HAHA) has been reported, and such antibodies are associated with reduced clinical responsiveness and with lower or absent trough levels [",
"      <a class=\"abstract\" href=\"UTD.htm?2/4/2120/abstract/4-7\">",
"       4-7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The addition of polyethylene glycol may reduce the antigenicity and may prolong the half-life of this anti-TNF-alpha agent. Nevertheless, in one clinical trial, anti-",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/6/39014?source=see_link\">",
"       certolizumab pegol",
"      </a>",
"      antibodies developed in 9 percent of patients who received this agent for Crohn&rsquo;s disease [",
"      <a class=\"abstract\" href=\"UTD.htm?2/4/2120/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Non-neutralizing antibodies have been reported in approximately 16 percent of patients treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"       etanercept",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?2/4/2120/abstract/9\">",
"       9",
"      </a>",
"      ]. However, neutralizing antibodies have not been described in patients treated with etanercept.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Human antichimeric antibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The development of antibodies against",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    is associated with an increased risk of infusion reactions, with a reduced response and duration of response to treatment, and with requirements for higher infliximab doses or more frequent dosing intervals in many patients [",
"    <a class=\"abstract\" href=\"UTD.htm?2/4/2120/abstract/6,10\">",
"     6,10",
"    </a>",
"    ]. The United States Food and Drug Administration approved the use of infliximab for the treatment of inflammatory disorders only if employed in conjunction with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    or other immunomodulators.",
"   </p>",
"   <p>",
"    The development of HACA is detected in 40 percent of patients when",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    is used alone but is significantly reduced by an uninterrupted course of infliximab at doses of &ge;3",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    and by co-administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?2/4/2120/abstract/11,12\">",
"     11,12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Crohn's disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a cohort of 125 consecutive patients with Crohn&rsquo;s disease treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    , the concentrations of infliximab and antibodies against infliximab were measured and compared with clinical data and adverse effects [",
"    <a class=\"abstract\" href=\"UTD.htm?2/4/2120/abstract/13\">",
"     13",
"    </a>",
"    ]. A mean of 3.9 infusions (range: 1 to 17) per patient were administered over a mean period of 10 months. The following observations were reported:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Antibodies against",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"       infliximab",
"      </a>",
"      were detected in 61 percent of patients.",
"     </li>",
"     <li>",
"      The presence of antibody concentrations of 8",
"      <span class=\"nowrap\">",
"       mcg/mL",
"      </span>",
"      or greater before an infusion predicted a shorter duration of response. The mean duration of response for patients with antibody concentrations above this level was only 35 days, compared with 71 days among patients with concentrations less than 8",
"      <span class=\"nowrap\">",
"       mcg/mL.",
"      </span>",
"     </li>",
"     <li>",
"      The relative risk of an infusion reaction associated with antibody concentrations of 8",
"      <span class=\"nowrap\">",
"       mcg/mL",
"      </span>",
"      or greater before an infusion was 2.4 (95% CI 1.7-3.7).",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"       Infliximab",
"      </a>",
"      concentrations were significantly lower at four weeks among patients who had had an infusion reaction than among patients who had never had an infusion reaction (median 1.2",
"      <span class=\"nowrap\">",
"       mcg/mL",
"      </span>",
"      versus 14.1",
"      <span class=\"nowrap\">",
"       mcg/mL).",
"      </span>",
"     </li>",
"     <li>",
"      Patients who had infusion reactions had a median duration of clinical response of 39 days, compared with 65 days among patients who did not have an infusion reaction.",
"     </li>",
"     <li>",
"      The use of concomitant immunosuppressive therapy (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/43/37559?source=see_link\">",
"       mercaptopurine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/44/22215?source=see_link\">",
"       mesalamine",
"      </a>",
"      ) predicted low titers of antibodies against",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"       infliximab",
"      </a>",
"      and high concentrations of infliximab four weeks after an infusion.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Rheumatoid arthritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Similar findings to those seen in Crohn&rsquo;s disease have been reported in studies of patients with rheumatoid arthritis (RA) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/4/2120/abstract/6,12,14\">",
"     6,12,14",
"    </a>",
"    ]. In one study, although low-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    (MTX) administration (7.5",
"    <span class=\"nowrap\">",
"     mg/week)",
"    </span>",
"    appeared to have little effect on the peak clinical response, it prolonged the duration of responses in most patients [",
"    <a class=\"abstract\" href=\"UTD.htm?2/4/2120/abstract/12\">",
"     12",
"    </a>",
"    ]. In addition, the likelihood of developing HACA correlated inversely with the dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    . Fifty-three percent of patients who received 1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    developed antibodies, compared with 21 percent of patients who received 3",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    and compared with 7 percent of those who received the 10",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    dose. Concomitant MTX reduced the frequency of HACA responses to 15, 7, and 0 percent in those three treatment groups, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?2/4/2120/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Antibodies to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    appear to be relatively specific to that molecule. Cross-reactions with other chimeric monoclonal antibodies such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    are unusual [",
"    <a class=\"abstract\" href=\"UTD.htm?2/4/2120/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Managing HACA",
"    </span>",
"    &nbsp;&mdash;&nbsp;The development of HACA has potentially important clinical effects. However, the full clinical impact of HACA is not clear. Solid data have linked HACA to the development of infusion reactions [",
"    <a class=\"abstract\" href=\"UTD.htm?2/4/2120/abstract/13\">",
"     13",
"    </a>",
"    ], but it is less clear that HACA is responsible for the blunting of clinical responses to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    that occur with regular administration over time. In addition, testing for HACA is not widely available, and there is no consensus about the optimal use of such assays.",
"   </p>",
"   <p>",
"    More than half of patients with RA receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    require increases in their regular dose over time or shortening of the interval at which the medication is administered [",
"    <a class=\"abstract\" href=\"UTD.htm?2/4/2120/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. Although this &ldquo;dose creep&rdquo; may be related to the formation of HACA, there is no evidence to confirm this theory. An alternative theory is that the need to increase infliximab doses over time simply reflects underdosing at the start of therapy. Thus, some patients with RA or Crohn&rsquo;s disease may benefit from infliximab given at doses higher than the recommended 3",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    or more frequently than every eight weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?2/4/2120/abstract/17\">",
"     17",
"    </a>",
"    ]. The usual approach to lessening clinical efficacy of infliximab is either to increase the dose or to increase the frequency with which the medication is administered.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Human antihuman antibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The formation of HAHA is associated with lower serum",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"     adalimumab",
"    </a>",
"    concentrations and with non-response to adalimumab treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?2/4/2120/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. As an example, the incidence of adalimumab antibody formation and the association of serum adalimumab concentrations with clinical response were evaluated in 272 consecutive patients with rheumatoid arthritis started on adalimumab and followed for three years [",
"    <a class=\"abstract\" href=\"UTD.htm?2/4/2120/abstract/7\">",
"     7",
"    </a>",
"    ]. The following findings were reported:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Anti-",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"       adalimumab",
"      </a>",
"      antibodies were detected in 76 patients (28 percent) during 156 weeks of treatment. Antibodies were detected within 28 weeks of beginning therapy in 67 percent of patients who became antibody-positive.",
"     </li>",
"     <li>",
"      Patients with high (&gt;100 arbitrary units [AU] per mL) or low (13 to 100",
"      <span class=\"nowrap\">",
"       AU/mL)",
"      </span>",
"      levels of anti-",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"       adalimumab",
"      </a>",
"      antibodies exhibited significantly lower adalimumab levels compared with patients without antibodies (0 and 5 versus 12",
"      <span class=\"nowrap\">",
"       mg/L).",
"      </span>",
"     </li>",
"     <li>",
"      Patients with high (&gt;100 arbitrary units [AU] per mL) or low (13 to 100",
"      <span class=\"nowrap\">",
"       AU/mL)",
"      </span>",
"      levels of anti-",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"       adalimumab",
"      </a>",
"      antibodies were significantly less likely to achieve minimal disease activity (DAS28 &lt;3.2) compared with patients without antibodies (6 and 18 versus 48 percent). Additionally, patients with anti-adalimumab antibodies were significantly more likely than those without such antibodies to discontinue study participation due to treatment failure (38 versus 14 percent).",
"     </li>",
"     <li>",
"      Patients with anti-",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"       adalimumab",
"      </a>",
"      antibodies were significantly less likely than those without such antibodies to have also received concomitant therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      (54 versus 82 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The data suggest that HAHA contributes to the reduced efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"     adalimumab",
"    </a>",
"    monotherapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     DEVELOPMENT OF AUTOANTIBODIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients treated with TNF-alpha inhibitors have an increased incidence of developing antinuclear antibodies (ANA) or antibodies to double-stranded deoxyribonucleic acid (anti-dsDNA) antibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?2/4/2120/abstract/11\">",
"     11",
"    </a>",
"    ]. Such antibodies have been reported in response to all TNF-alpha inhibitors but may be more common with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    The following observations highlight the range of findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      During six-month clinical trials of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"       etanercept",
"      </a>",
"      in patients with RA, 11 percent of 323 patients became ANA-positive, and 15 percent developed anti-dsDNA antibodies. These figures were significantly higher than the corresponding figures among placebo-treated patients, which were 4 percent for ANA and 5 percent for anti-dsDNA antibodies [",
"      <a class=\"abstract\" href=\"UTD.htm?2/4/2120/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      During the ATTRACT trial of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"       infliximab",
"      </a>",
"      in RA, 62 percent of patients treated with infliximab developed ANA, compared with 27 percent of placebo-treated patients [",
"      <a class=\"abstract\" href=\"UTD.htm?2/4/2120/abstract/19\">",
"       19",
"      </a>",
"      ]. In addition, anti-dsDNA antibodies developed in 15 percent of patients treated with infliximab, compared with none among the placebo-treated patients. Most of the anti-dsDNA antibodies observed were of the IgM isotype. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/10/10410?source=see_link&amp;anchor=H4#H4\">",
"       \"Randomized clinical trials of tumor necrosis factor inhibitors in rheumatoid arthritis\", section on 'Infliximab'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Six patients in the ATTRACT trial developed lupus-like syndromes [",
"      <a class=\"abstract\" href=\"UTD.htm?2/4/2120/abstract/19\">",
"       19",
"      </a>",
"      ]. In each case, the new clinical symptoms resolved after the TNF-alpha inhibitor was discontinued.",
"     </li>",
"     <li>",
"      Data on the development of ANA and anti-dsDNA antibodies among patients treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"       adalimumab",
"      </a>",
"      are few. There appears to be a slightly higher incidence of ANA among patients treated with adalimumab, but the clinical significance of this (if any) remains unclear. Lupus-like syndromes have been reported in some adalimumab-treated patients [",
"      <a class=\"abstract\" href=\"UTD.htm?2/4/2120/abstract/20,21\">",
"       20,21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"       infliximab",
"      </a>",
"      and MTX show a low incidence of induced anticardiolipin antibodies [",
"      <a class=\"abstract\" href=\"UTD.htm?2/4/2120/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      ANA occurred in 8 percent of patients treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/6/39014?source=see_link\">",
"       certolizumab pegol",
"      </a>",
"      for Crohn&rsquo;s disease in one study [",
"      <a class=\"abstract\" href=\"UTD.htm?2/4/2120/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     AUTOIMMUNE DISEASES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several lines of evidence support the concept that a small minority of patients treated with TNF-alpha inhibitors develops autoimmune conditions as a result of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?2/4/2120/abstract/23\">",
"     23",
"    </a>",
"    ]. These lines of evidence include [",
"    <a class=\"abstract\" href=\"UTD.htm?2/4/2120/abstract/21\">",
"     21",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The temporal association between the use of TNF-alpha inhibitor therapy and the development of clinical features of an autoimmune disease",
"     </li>",
"     <li>",
"      The resolution of the autoimmune condition following the cessation of targeted TNF-alpha treatment",
"     </li>",
"     <li>",
"      The original appearance in some cases of leukocytoclastic vasculitis at the site of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"       etanercept",
"      </a>",
"      injections",
"     </li>",
"     <li>",
"      The reappearance or worsening of the symptoms upon re-exposure to the TNF-alpha inhibitor in a majority of cases in which rechallenge has been attempted [",
"      <a class=\"abstract\" href=\"UTD.htm?2/4/2120/abstract/21\">",
"       21",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The majority of cases of autoimmune disease reported among patients receiving TNF-alpha inhibitors have been vasculitic syndromes, lupus-like syndromes, or psoriatic skin lesions.",
"   </p>",
"   <p>",
"    Most cases of vasculitis are confined to the skin and demonstrate findings of a leukocytoclastic vasculitis. Most cases of drug-induced lupus are characterized by skin and pleuropericardial abnormalities, along with the formation of autoantibodies such as those to dsDNA, the Sm antigen, or histones. Renal and neurological manifestations are extremely rare, and the nature of their association with TNF-alpha inhibitor use remains unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?2/4/2120/abstract/24\">",
"     24",
"    </a>",
"    ]. The relationship between TNF-alpha inhibitor use and the development of ILD is less clear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Vasculitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a series that attempted to analyze all cases of autoimmune disease induced by TNF-alpha inhibitors and reported in the medical literature through December 2006, 113 cases of vasculitis, 92 cases of lupus, and 24 cases of interstitial lung disease were described [",
"    <a class=\"abstract\" href=\"UTD.htm?2/4/2120/abstract/21\">",
"     21",
"    </a>",
"    ]. Ninety-eight (87 percent) of the patients with vasculitis had cutaneous involvement. Among these, the following lesions were observed:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Palpable purpura &mdash; 55 patients (57 percent)",
"     </li>",
"     <li>",
"      Erythematous",
"      <span class=\"nowrap\">",
"       papules/macules/punctate",
"      </span>",
"      lesions &mdash; 11 (11 percent)",
"     </li>",
"     <li>",
"      Ulcers &mdash; 9 (9 percent)",
"     </li>",
"     <li>",
"      Nodules &mdash; 9 (9 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In terms of visceral involvement by vasculitis, the peripheral nerves and kidneys were affected in 18 (16 percent) and 15 (13 percent) patients, respectively.",
"   </p>",
"   <p>",
"    Eighty-three of the 113 vasculitis cases were confirmed histopathologically. Among these, leukocytoclastic vasculitis was reported in 52 patients (63 percent), necrotizing vasculitis in 14 (17 percent), lymphocytic vasculitis in 5 (6 percent), and other findings in 12 (14 percent).",
"   </p>",
"   <p>",
"    Ninety-two percent of the cases of vasculitis resolved following the discontinuation of TNF-alpha inhibitors. Among the 16 patients rechallenged with a TNF-alpha inhibitor, vasculitis recurred in 12.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Systemic lupus erythematosus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among the 92 patients with SLE associated with TNF-alpha inhibitor use in the series described above [",
"    <a class=\"abstract\" href=\"UTD.htm?2/4/2120/abstract/21\">",
"     21",
"    </a>",
"    ], information about the specific American College of Rheumatology (ACR) criteria for the diagnosis of SLE was available in 72 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?2/4/2120/abstract/25\">",
"     25",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fifty-seven patients (79 percent) were ANA-positive.",
"     </li>",
"     <li>",
"      Fifty-two (72 percent) had anti-dsDNA antibodies.",
"     </li>",
"     <li>",
"      Forty-eight (67 percent) had cutaneous features.",
"     </li>",
"     <li>",
"      Twenty-two (31 percent) had arthritis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Among the 72 patients on whom information regarding ACR criteria were available, only 37 (51 percent) fulfilled four or more criteria. In addition, this figure decreased to 35 percent if criteria that existed before the start of TNF-alpha inhibitors were excluded.",
"   </p>",
"   <p>",
"    In this series and others, serositis was less common than rash or arthritis, and renal and neurological symptoms were rare [",
"    <a class=\"abstract\" href=\"UTD.htm?2/4/2120/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. The frequency of antihistone antibodies, a hallmark of drug-induced lupus (with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/34/36391?source=see_link\">",
"     procainamide",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/57/15254?source=see_link\">",
"     hydralazine",
"    </a>",
"    ), ranged from 17 [",
"    <a class=\"abstract\" href=\"UTD.htm?2/4/2120/abstract/9\">",
"     9",
"    </a>",
"    ] to 57 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?2/4/2120/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The rarity of drug-induced lupus due to TNF inhibitors was illustrated in observations from a large French registry, in which the incidence among patients treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    was approximately 0.2 percent, with too few data for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"     adalimumab",
"    </a>",
"    to make an accurate estimate [",
"    <a class=\"abstract\" href=\"UTD.htm?2/4/2120/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The symptoms and signs of SLE resolved following the discontinuation of the TNF-alpha inhibitor in 71 of the 72 patients on whom information regarding disease outcome were available in the large series described above [",
"    <a class=\"abstract\" href=\"UTD.htm?2/4/2120/abstract/21\">",
"     21",
"    </a>",
"    ]. Resolution of SLE was seen in other series as well, although many of the patients also received glucocorticoids for the related symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?2/4/2120/abstract/26\">",
"     26",
"    </a>",
"    ]. The use of concomitant MTX, which is thought to reduce the frequency of autoantibodies when using anti-TNF, did not appear to protect against the development of anti-TNF-induced lupus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Interstitial lung disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to vasculitis and SLE, there have also been reports of interstitial lung disease (ILD) occurring in association with TNF-alpha inhibitors use [",
"    <a class=\"abstract\" href=\"UTD.htm?2/4/2120/abstract/21\">",
"     21",
"    </a>",
"    ]. In some reported cases of ILD associated with TNF-alpha inhibitor use, the lung disease has taken an aggressive course. However, in most such cases, the patients have had underlying disorders such as RA that place them at risk for ILD, making it impossible to exclude confounding by indication as a factor in these reports.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Uveitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ocular inflammation of the uveal tract (uveitis) has been reported in association with the use of anti-TNF-alpha agents. One registry-based study that included spontaneous reports of uveitis during the period from January 1, 1998 through January 1, 2006 noted 43 cases in patients who were receiving anti-TNF-alpha therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?2/4/2120/abstract/28\">",
"     28",
"    </a>",
"    ]. After exclusion of patients with diseases associated with an increased risk of uveitis (eg, ankylosing spondylitis, Crohn&rsquo;s disease, or juvenile idiopathic arthritis [JIA]), the numbers of patients taking",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"     adalimumab",
"    </a>",
"    in the remaining cases were 20, four, and two, respectively. The authors of this study concluded that, although the risk of uveitis was greater, this should not influence the initial choice of anti-TNF-alpha agent, but they did suggest that, for a patient without an underlying disease known to predispose to uveitis who develops uveal inflammation during treatment with etanercept, a switch to an anti-TNF-alpha antibody (infliximab or adalimumab) would be an option to consider.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Psoriatic skin lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Psoriatic skin lesions may be induced by anti-TNF-alpha therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/55/40825?source=see_link&amp;anchor=H28#H28\">",
"     \"Tumor necrosis factor-alpha inhibitors: An overview of adverse effects\", section on 'Psoriatic skin lesions'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The risk of forming neutralizing antibodies varies with the specific type of TNF-alpha inhibitor. Neutralizing antibodies have not been reported with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"       etanercept",
"      </a>",
"      , a soluble fusion protein.",
"     </li>",
"     <li>",
"      Human antichimeric antibodies formed in",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"       infliximab",
"      </a>",
"      -treated patients can lead to an increased risk of infusion reactions, to a reduced duration of response to treatment, and to requirements for higher infliximab doses or for more frequent dosing intervals. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Human antichimeric antibodies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Increasing levels of neutralizing antibodies lead to reduced clinical benefit in a proportionately higher number of patients treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"       adalimumab",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Human antihuman antibodies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Co-administration of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      reduces the incidence of neutralizing antibodies in",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"       infliximab",
"      </a>",
"      - and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"       adalimumab",
"      </a>",
"      -treated patients. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Human antichimeric antibodies'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Human antihuman antibodies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The formation of antinuclear antibodies and antibodies to dsDNA has been reported in response to all TNF-alpha inhibitors but may be more common with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"       infliximab",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Development of autoantibodies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cases of vasculitis and lupus-like syndromes have been reported in association with TNF-alpha inhibitor use. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Autoimmune diseases'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most cases of vasculitis and lupus reported in association with TNF-alpha inhibitor use resolve following discontinuation of the TNF-alpha inhibitor. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Vasculitis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H13\">",
"       'Systemic lupus erythematosus'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Psoriatic skin lesions that develop during anti-TNF-alpha treatment often resolve with or without discontinuation of treatment. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Psoriatic skin lesions'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/4/2120/abstract/1\">",
"      Serio RN. Infliximab treatment of sarcoidosis. Ann Pharmacother 2003; 37:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/4/2120/abstract/2\">",
"      Utz JP, Limper AH, Kalra S, et al. Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis. Chest 2003; 124:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/4/2120/abstract/3\">",
"      Sandborn WJ, Hanauer SB, Katz S, et al. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2001; 121:1088.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/4/2120/abstract/4\">",
"      Bartelds GM, Wolbink GJ, Stapel S, et al. High levels of human anti-human antibodies to adalimumab in a patient not responding to adalimumab treatment. Ann Rheum Dis 2006; 65:1249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/4/2120/abstract/5\">",
"      Bartelds GM, Wijbrandts CA, Nurmohamed MT, et al. Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis 2007; 66:921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/4/2120/abstract/6\">",
"      Radstake TR, Svenson M, Eijsbouts AM, et al. Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis. Ann Rheum Dis 2009; 68:1739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/4/2120/abstract/7\">",
"      Bartelds GM, Krieckaert CL, Nurmohamed MT, et al. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA 2011; 305:1460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/4/2120/abstract/8\">",
"      Schreiber S, Khaliq-Kareemi M, Lawrance IC, et al. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med 2007; 357:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/4/2120/abstract/9\">",
"      De Bandt M, Sibilia J, Le Lo&euml;t X, et al. Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey. Arthritis Res Ther 2005; 7:R545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/4/2120/abstract/10\">",
"      Wolbink GJ, Vis M, Lems W, et al. Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum 2006; 54:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/4/2120/abstract/11\">",
"      Elliott MJ, Maini RN, Feldmann M, et al. Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis. Lancet 1994; 344:1125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/4/2120/abstract/12\">",
"      Maini RN, Breedveld FC, Kalden JR, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998; 41:1552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/4/2120/abstract/13\">",
"      Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003; 348:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/4/2120/abstract/14\">",
"      Haraoui B, Cameron L, Ouellet M, White B. Anti-infliximab antibodies in patients with rheumatoid arthritis who require higher doses of infliximab to achieve or maintain a clinical response. J Rheumatol 2006; 33:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/4/2120/abstract/15\">",
"      Wagner CL, Schantz A, Barnathan E, et al. Consequences of immunogenicity to the therapeutic monoclonal antibodies ReoPro and Remicade. Dev Biol (Basel) 2003; 112:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/4/2120/abstract/16\">",
"      Ollendorf DA, Massarotti E, Birbara C, Burgess SM. Frequency, predictors, and economic impact of upward dose adjustment of infliximab in managed care patients with rheumatoid arthritis. J Manag Care Pharm 2005; 11:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/4/2120/abstract/17\">",
"      St Clair EW, Wagner CL, Fasanmade AA, et al. The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002; 46:1451.",
"     </a>",
"    </li>",
"    <li>",
"     Etanercept (Enbrel) package insert.",
"    </li>",
"    <li>",
"     Infliximab (Remicade) package insert.",
"    </li>",
"    <li>",
"     Adalimumab (Humira) package insert.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/4/2120/abstract/21\">",
"      Ramos-Casals M, Brito-Zer&oacute;n P, Mu&ntilde;oz S, et al. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine (Baltimore) 2007; 86:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/4/2120/abstract/22\">",
"      Visvanathan S, Wagner C, Smolen J, et al. IgG and IgM anticardiolipin antibodies following treatment with infliximab plus methotrexate in patients with early rheumatoid arthritis. Arthritis Rheum 2006; 54:2840.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/4/2120/abstract/23\">",
"      De Bandt M. Lessons for lupus from tumour necrosis factor blockade. Lupus 2006; 15:762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/4/2120/abstract/24\">",
"      Stokes MB, Foster K, Markowitz GS, et al. Development of glomerulonephritis during anti-TNF-alpha therapy for rheumatoid arthritis. Nephrol Dial Transplant 2005; 20:1400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/4/2120/abstract/25\">",
"      Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40:1725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/4/2120/abstract/26\">",
"      Williams EL, Gadola S, Edwards CJ. Anti-TNF-induced lupus. Rheumatology (Oxford) 2009; 48:716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/4/2120/abstract/27\">",
"      Soforo E, Baumgartner M, Francis L, et al. Induction of systemic lupus erythematosus with tumor necrosis factor blockers. J Rheumatol 2010; 37:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/4/2120/abstract/28\">",
"      Lim LL, Fraunfelder FW, Rosenbaum JT. Do tumor necrosis factor inhibitors cause uveitis? A registry-based study. Arthritis Rheum 2007; 56:3248.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7974 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-89.32.226.102-C070ECA3F8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_4_2120=[""].join("\n");
var outline_f2_4_2120=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENERAL ISSUES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      TNF-alpha antagonists",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      NEUTRALIZING ANTIBODIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Human antichimeric antibodies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Crohn's disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Managing HACA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Human antihuman antibodies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      DEVELOPMENT OF AUTOANTIBODIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      AUTOIMMUNE DISEASES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Vasculitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Systemic lupus erythematosus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Interstitial lung disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Uveitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Psoriatic skin lesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/10/10410?source=related_link\">",
"      Randomized clinical trials of tumor necrosis factor inhibitors in rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/38/24169?source=related_link\">",
"      Tumor necrosis factor-alpha inhibitors and mycobacterial infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/55/40825?source=related_link\">",
"      Tumor necrosis factor-alpha inhibitors: An overview of adverse effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/49/32538?source=related_link\">",
"      Tumor necrosis factor-alpha inhibitors: Risk of bacterial, viral, and fungal infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/53/33624?source=related_link\">",
"      Tumor necrosis factor-alpha inhibitors: Risk of malignancy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_4_2121="Antibiotic lock therapy for treatment of catheter-related bloodstream infections";
var content_f2_4_2121=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Antibiotic lock therapy for treatment of catheter-related bloodstream infections",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/4/2121/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/4/2121/contributors\">",
"     Heather L VandenBussche, PharmD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/4/2121/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/4/2121/contributors\">",
"     Daniel J Sexton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/4/2121/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/4/2121/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?2/4/2121/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 8, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H50341274\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Central venous catheter (CVC) use has increased substantially in recent years, and associated infections have become a frequent complication of catheter use. As an example, an estimated 250,000 to 500,000 catheter-related bloodstream infections (CRBSI) occur annually in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?2/4/2121/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. These infections are a significant cause of morbidity and mortality among patients receiving chemotherapy, parenteral nutrition, and hemodialysis. Infection rates are dependent on the type of CVC used and are reported as the number of bloodstream infections per 1000 intravascular device days. CVC infection rates are highest with short-term noncuffed, nontunneled hemodialysis and multilumen catheters, and lowest with subcutaneous central venous ports [",
"    <a class=\"abstract\" href=\"UTD.htm?2/4/2121/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Management of CRBSI depends on the decision to salvage, exchange, or remove the catheter. Antibiotic lock therapy has been used in conjunction with systemic antibiotics in attempts to salvage infected long-term catheters (tunneled catheters and subcutaneous central ports), and its use will be reviewed here.",
"   </p>",
"   <p>",
"    Diagnosis, general management, and prevention of CRBSI are reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/23/375?source=see_link\">",
"     \"Diagnosis of intravascular catheter-related infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/20/7498?source=see_link\">",
"     \"Treatment of intravascular catheter-related infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/8/29834?source=see_link\">",
"     \"Tunneled, cuffed hemodialysis catheter-related bacteremia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/53/31578?source=see_link\">",
"     \"Prevention of intravascular catheter-related infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H50341281\">",
"    <span class=\"h1\">",
"     RATIONALE FOR USE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antibiotic lock therapy (ALT) involves instillation of a highly concentrated antibiotic solution into an intravascular catheter lumen for the purpose of sterilization in order to treat catheter-related bloodstream infections (CRBSI), minimize associated complications, and avoid catheter removal [",
"    <a class=\"abstract\" href=\"UTD.htm?2/4/2121/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/20/7498?source=see_link&amp;anchor=H5#H5\">",
"     \"Treatment of intravascular catheter-related infections\", section on 'Salvage'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/8/29834?source=see_link&amp;anchor=H19#H19\">",
"     \"Tunneled, cuffed hemodialysis catheter-related bacteremia\", section on 'Catheter management'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Intraluminal colonization and infection of central venous catheters (CVCs) are associated with the development of microbial biofilm on catheter surfaces. Bacteria in a biofilm can be difficult to eradicate with traditional systemic antibiotic administration and can lead to recurrent CRBSI [",
"    <a class=\"abstract\" href=\"UTD.htm?2/4/2121/abstract/5-8\">",
"     5-8",
"    </a>",
"    ]. Antibiotic concentrations must be 100- to 1000-fold greater to kill sessile bacteria within a biofilm as compared with planktonic bacteria [",
"    <a class=\"abstract\" href=\"UTD.htm?2/4/2121/abstract/7,9\">",
"     7,9",
"    </a>",
"    ]. The antibiotic lock is a highly concentrated antibiotic solution, often combined with an anticoagulant such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    , administered in an amount sufficient to fill and dwell in the catheter lumen when the catheter is not in use. Anticoagulants are thought to be beneficial in ALT for treatment of CRBSI by interfering with fibrin formation and allowing increased antibiotic penetration into microbial biofilm. Dwell times may range from four to six hours to three days, depending on solution stability and amount of time available when the catheter is not in use. Antibiotic lock solutions should be withdrawn from the catheter when it is needed for intravenous access to avoid systemic exposure to high concentrations of antibiotics",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    anticoagulants that can result in toxic effects, particularly with prolonged use [",
"    <a class=\"abstract\" href=\"UTD.htm?2/4/2121/abstract/10,11\">",
"     10,11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13928254\">",
"    <span class=\"h1\">",
"     INDICATIONS AND CONTRAINDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are few high quality data to guide the use of antibiotic lock therapy (ALT) (see",
"    <a class=\"local\" href=\"#H50341318\">",
"     'Efficacy'",
"    </a>",
"    below). We typically use ALT as adjunctive therapy with systemic antibiotics only when catheter salvage in the setting of a catheter-related bloodstream infection (CRBSI) is an appropriate option. This includes adults and children who meet the following criteria:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Have a long-term intravascular device (&gt;14 days), including tunneled catheters and implanted ports",
"     </li>",
"     <li>",
"      Are clinically and hemodynamically stable",
"     </li>",
"     <li>",
"      Have infections due to coagulase-negative staphylococci, Gram-negative rods, or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"       vancomycin",
"      </a>",
"      -sensitive enterococci",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In general, catheter removal is preferred and ALT is NOT recommended to treat CRBSI in the following circumstances [",
"    <a class=\"abstract\" href=\"UTD.htm?2/4/2121/abstract/12-15\">",
"     12-15",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Complicated CRBSI (suppurative thrombophlebitis, endocarditis, osteomyelitis, or other metastatic infection)",
"     </li>",
"     <li>",
"      Severe sepsis or hemodynamic instability",
"     </li>",
"     <li>",
"      Persistent bacteremia despite 72 hours of antibiotic therapy to which the infecting organism is susceptible",
"     </li>",
"     <li>",
"      Infections caused by Staphylococcus aureus, Pseudomonas aeruginosa, fungi, or mycobacteria",
"     </li>",
"     <li>",
"      Infections caused by Bacillus species, Micrococcus species, or Propionibacteria after blood culture contamination is ruled out",
"     </li>",
"     <li>",
"      Short-term central venous catheters (CVCs) (indwelling &lt;14 days)",
"     </li>",
"     <li>",
"      Tunnel infections, port abscesses, or exit site infections",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Once catheter salvage with ALT is initiated, patients must be monitored carefully for evidence of ongoing systemic infection. Salvage attempts should be aborted in the setting of persistent infection. (See",
"    <a class=\"local\" href=\"#H13928500\">",
"     'Monitoring'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    These suggestions are consistent with recommendations from the Infectious Diseases Society of America [",
"    <a class=\"abstract\" href=\"UTD.htm?2/4/2121/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H50341318\">",
"    <span class=\"h1\">",
"     EFFICACY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data on the efficacy of antibiotic lock therapy (ALT) are limited mainly to small observational studies that are generally supportive of ALT for catheter-related bloodstream infection (CRBSI) in various patient populations (hemodialysis,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/40/42628?source=see_link\">",
"     total parenteral nutrition",
"    </a>",
"    , oncologic) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/4/2121/abstract/3,16-39\">",
"     3,16-39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the only randomized, placebo-controlled trial of ALT, there was no significant difference in failure to cure (7 of 21 [33 percent] versus 13 of 23 [57 percent]) or relapse by day 180 (3 of 21 [14 percent] versus 9 of 23 [39 percent]) with ALT and systemic antibiotics as compared with systemic antibiotics only [",
"      <a class=\"abstract\" href=\"UTD.htm?2/4/2121/abstract/30\">",
"       30",
"      </a>",
"      ]. There was a trend toward benefit of ALT, but this study was limited by a lack of statistical power with only 44 episodes of CRBSI. However, differences of this magnitude would be clinically meaningful if real.",
"     </li>",
"     <li>",
"      In a meta-analysis of five observational studies and the randomized trial above, a smaller proportion of patients treated with ALT plus systemic antibiotics required catheter replacement (10 versus 33 percent with systemic antibiotics alone, odds ratio [OR] 0.20, 95% CI 0.10-0.39) [",
"      <a class=\"abstract\" href=\"UTD.htm?2/4/2121/abstract/40\">",
"       40",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Definitions of CRBSI, catheter types (totally implanted subcutaneous ports, tunneled and nontunneled hemodialysis and nonhemodialysis catheters), and measures of treatment success varied between studies. Nevertheless, ALT combined with systemic antibiotic therapy is an option for catheter salvage in certain clinical situations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H50341333\">",
"    <span class=\"h2\">",
"     Hemodialysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Observational studies of ALT administered between hemodialysis sessions in adults with end-stage renal disease and tunneled catheters have reported success rates of 41 to 100 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?2/4/2121/abstract/16-22\">",
"     16-22",
"    </a>",
"    ], which are variable by organism. Patients with S. aureus-infected catheters had particularly low rates of success (40 to 41 percent) and high rates of infectious complications (20 to 25 percent) when fever persisted 48 hours after initiating ALT and systemic antibiotics [",
"    <a class=\"abstract\" href=\"UTD.htm?2/4/2121/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. Success rates were more favorable with gram-negative (87 percent), coagulase-negative staphylococcal (75 percent), and enterococcal (61 percent) infections [",
"    <a class=\"abstract\" href=\"UTD.htm?2/4/2121/abstract/19,22\">",
"     19,22",
"    </a>",
"    ]. These data support the recommendation by the Infectious Diseases Society of America to avoid ALT for catheter salvage in CRBSI caused by S. aureus unless there are contraindications to catheter removal, such as a significant risk for bleeding or lack of available alternative venous access sites [",
"    <a class=\"abstract\" href=\"UTD.htm?2/4/2121/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H50341340\">",
"    <span class=\"h2\">",
"     Total parenteral nutrition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Six small observational studies of ALT in adults requiring home parenteral nutrition reported success rates of 25 to 100 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?2/4/2121/abstract/3,23-27\">",
"     3,23-27",
"    </a>",
"    ]. In particular, ALT had low success in patients with candidemia [",
"    <a class=\"abstract\" href=\"UTD.htm?2/4/2121/abstract/26\">",
"     26",
"    </a>",
"    ] or a port [",
"    <a class=\"abstract\" href=\"UTD.htm?2/4/2121/abstract/27\">",
"     27",
"    </a>",
"    ]. None of the studied lock solutions contained",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    , and treatment regimens varied in antibiotic choice, dwell time, duration of therapy, and use of concomitant systemic antibiotics. Two studies reported similar success rates of ALT alone compared with ALT and systemic antibiotics, but these were nonrandomized and subject to selection bias and may have underestimated a difference between groups due to a lack of statistical power [",
"    <a class=\"abstract\" href=\"UTD.htm?2/4/2121/abstract/3,23\">",
"     3,23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H50341354\">",
"    <span class=\"h2\">",
"     Children",
"    </span>",
"    &nbsp;&mdash;&nbsp;Current guidelines recommend ALT with systemic antibiotics for catheter salvage in children with CRBSI when clinically possible because of vascular access difficulties in this patient population [",
"    <a class=\"abstract\" href=\"UTD.htm?2/4/2121/abstract/12\">",
"     12",
"    </a>",
"    ]. Three studies of ALT in 34 children with malignancies reported success rates of 30, 83, and 100 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?2/4/2121/abstract/33-35\">",
"     33-35",
"    </a>",
"    ]. The low catheter salvage rate seen in one of those studies [",
"    <a class=\"abstract\" href=\"UTD.htm?2/4/2121/abstract/35\">",
"     35",
"    </a>",
"    ] may have been associated with its high proportion of implanted ports (74 percent of patients) and lack of ALT initiation until patients failed 48 hours of systemic",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H50341361\">",
"    <span class=\"h2\">",
"     Port-related CRBSI",
"    </span>",
"    &nbsp;&mdash;&nbsp;ALT is an attractive treatment option for CRBSI of implanted vascular ports because removal of a totally implanted device is a challenge, particularly if performed multiple times in the same patient. Success rates of ALT in patients with port-related infections vary from 18 to 100 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?2/4/2121/abstract/18,27,35-38\">",
"     18,27,35-38",
"    </a>",
"    ]. Poor success was observed in patients who did not receive ALT until after systemic antibiotics failed and in patients whose lock solutions did not contain",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?2/4/2121/abstract/27,35,36\">",
"     27,35,36",
"    </a>",
"    ]. One study comparing",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    with teicoplanin locks (both containing heparin 100",
"    <span class=\"nowrap\">",
"     units/mL)",
"    </span>",
"    reported higher success rates with teicoplanin, speculating that its improved binding to siliconized polymers may be beneficial for port-related infections [",
"    <a class=\"abstract\" href=\"UTD.htm?2/4/2121/abstract/38\">",
"     38",
"    </a>",
"    ]. Four additional studies that reported ALT success rates of 67 to 93 percent included patients with venous access ports but did not describe separate results for port-related CRBSI [",
"    <a class=\"abstract\" href=\"UTD.htm?2/4/2121/abstract/28,30-32\">",
"     28,30-32",
"    </a>",
"    ]. Current guidelines recommend ALT for port salvage in similar clinical situations as for other central venous catheters [",
"    <a class=\"abstract\" href=\"UTD.htm?2/4/2121/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H112483117\">",
"    <span class=\"h1\">",
"     ANTIBIOTIC LOCK SOLUTION CHOICE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ideally, the selected solution should be chemically stable, be active against biofilm-associated organisms, and have been studied for treatment of catheter-related bloodstream infection (CRBSI) in similar clinical situations.",
"   </p>",
"   <p>",
"    Most catheter-related infections are caused by staphylococci and gram-negative bacilli; therefore, antibiotics commonly used in antibiotic lock therapy (ALT) include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/2/4136?source=see_link\">",
"     cefazolin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/0/17415?source=see_link\">",
"     ceftazidime",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/10/36000?source=see_link\">",
"     gentamicin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?2/4/2121/abstract/41\">",
"     41",
"    </a>",
"    ]. Specific antibiotic selection for ALT should be driven by culture and susceptibility results when available. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/37/37464?source=see_link\">",
"     \"Epidemiology, pathogenesis, and microbiology of intravascular catheter infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/20/7498?source=see_link&amp;anchor=H10#H10\">",
"     \"Treatment of intravascular catheter-related infections\", section on 'Tailoring therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The selection of antibiotic lock solution further depends on the catheter type, need for an anticoagulant, and the amount of time available for the solution to dwell in the catheter between venous access for other purposes. For example, an antibiotic lock solution for an infected hemodialysis catheter should contain 2000 to 5000",
"    <span class=\"nowrap\">",
"     units/mL",
"    </span>",
"    of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    and should be stable for 48 to 72 hours to dwell in the catheter lumen between hemodialysis sessions. Individual patient characteristics such as body weight and allergies may also affect antibiotic choice as lock solutions may leak or be flushed into the venous circulation, causing potential side effects from unintentional systemic exposure.",
"   </p>",
"   <p>",
"    <span class=\"nowrap\">",
"     Antibiotic/anticoagulant",
"    </span>",
"    solutions frequently used in practice include the following (",
"    <a class=\"graphic graphic_table graphicRef83938 \" href=\"UTD.htm?0/21/349\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <span class=\"nowrap\">",
"       <a class=\"drug drug_general\" href=\"UTD.htm?4/2/4136?source=see_link\">",
"        Cefazolin",
"       </a>",
"       /",
"       <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"        heparin",
"       </a>",
"      </span>",
"      &ndash; Cefazolin (1 mL of 10",
"      <span class=\"nowrap\">",
"       mg/mL",
"      </span>",
"      in normal saline solution) plus heparin (1 mL of 10,000 units per mL solution)",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       <a class=\"drug drug_general\" href=\"UTD.htm?17/0/17415?source=see_link\">",
"        Ceftazidime",
"       </a>",
"       /",
"       <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"        heparin",
"       </a>",
"      </span>",
"      &ndash; Ceftazidime (1 mL of 20",
"      <span class=\"nowrap\">",
"       mg/mL",
"      </span>",
"      in normal saline solution) plus heparin (1 mL of 10,000 units per mL solution)",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       <a class=\"drug drug_general\" href=\"UTD.htm?35/10/36000?source=see_link\">",
"        Gentamicin",
"       </a>",
"       /",
"       <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"        heparin",
"       </a>",
"      </span>",
"      &ndash; Gentamicin (0.5 mL of 4",
"      <span class=\"nowrap\">",
"       mg/mL",
"      </span>",
"      in normal saline solution) plus heparin (0.5 mL of 10,000 units per mL solution) plus 1 mL of normal saline solution",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"        Vancomycin",
"       </a>",
"       /",
"       <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"        heparin",
"       </a>",
"      </span>",
"      &ndash; Vancomycin (1 mL of 10",
"      <span class=\"nowrap\">",
"       mg/mL",
"      </span>",
"      in normal saline solution) plus heparin (1 mL of 10,000 units per mL solution) plus 0.5 mL of normal saline solution",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These are based on a final volume of 2 mL and should be accordingly adjusted if larger volumes are needed to fill the catheter lumen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4202042\">",
"    <span class=\"h2\">",
"     Antibiotic",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no standard antibiotic or dosing regimen for use in ALT. Furthermore, comparing efficacy of antibiotic lock solutions across studies is difficult because different microbial strains with diverse susceptibility profiles were included, and outcome measures for determining antimicrobial effects varied between the studies. Because of the high antibiotic levels required to kill bacteria within a biofilm, the end antibiotic concentration in the solution should exceed 1000-fold the minimum inhibitory concentration (MIC) of the organism treated. Although lock solutions containing lower antibiotic and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    concentrations are physically and chemically stable [",
"    <a class=\"abstract\" href=\"UTD.htm?2/4/2121/abstract/42,43\">",
"     42,43",
"    </a>",
"    ], they have not been evaluated for in vitro efficacy in a biofilm catheter model or for treatment of CRBSI. These low concentrations are unlikely to be effective in killing biofilm-embedded bacteria and cannot be recommended for treatment of CRBSI.",
"   </p>",
"   <p>",
"    Antibiotics commonly used in antibiotic lock solutions with anticoagulants include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/0/17415?source=see_link\">",
"     ceftazidime",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/2/4136?source=see_link\">",
"     cefazolin",
"    </a>",
"    to cover the most common causes of catheter-related infections (",
"    <a class=\"graphic graphic_table graphicRef83938 \" href=\"UTD.htm?0/21/349\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/4/2121/abstract/44-46\">",
"     44-46",
"    </a>",
"    ]. When anticoagulants are contraindicated, only antibiotics that have been shown to be stable and effective when used alone should be administered (",
"    <a class=\"graphic graphic_table graphicRef83939 \" href=\"UTD.htm?29/45/30429\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/4/2121/abstract/47-52\">",
"     47-52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21997797\">",
"    <span class=\"h2\">",
"     Anticoagulant",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anticoagulants are often added to the antibiotic lock solution because they are thought to facilitate increased antibiotic penetration into microbial biofilm by interfering with fibrin formation within the catheter lumen [",
"    <a class=\"abstract\" href=\"UTD.htm?2/4/2121/abstract/53,54\">",
"     53,54",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     Heparin",
"    </a>",
"    is the most common anticoagulant used in ALT; certain antibiotic-heparin combinations are physically compatible without precipitation and remain chemically stable or active for prolonged periods of time (",
"    <a class=\"graphic graphic_table graphicRef83938 \" href=\"UTD.htm?0/21/349\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/4/2121/abstract/12,16,44-47,55-57\">",
"     12,16,44-47,55-57",
"    </a>",
"    ]. Disadvantages of heparin include concentration-dependent incompatibility with certain antibiotics, risk of bleeding from systemic anticoagulation, and development of heparin-induced thrombocytopenia [",
"    <a class=\"abstract\" href=\"UTD.htm?2/4/2121/abstract/11\">",
"     11",
"    </a>",
"    ]. Studies report that heparin may stimulate S. aureus biofilm formation, although this finding is not universally accepted [",
"    <a class=\"abstract\" href=\"UTD.htm?2/4/2121/abstract/58-60\">",
"     58-60",
"    </a>",
"    ]. We use heparin in the antibiotic lock solution unless there is a contraindication to heparin (eg, heparin-induced thrombocytopenia). In some patients, namely infants and young children, in whom large systemic doses of heparin would be dangerous if the lock solution were inadvertently flushed, we use lower concentrations of heparin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21998020\">",
"    <span class=\"h2\">",
"     Other solution additives",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies investigating the effects of N-acetylcysteine, used to degrade mature biofilm matrices, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/7/40053?source=see_link\">",
"     tigecycline",
"    </a>",
"    combination locks have reported synergistic antimicrobial effects and promising catheter salvage rates for a variety of biofilm-associated organisms [",
"    <a class=\"abstract\" href=\"UTD.htm?2/4/2121/abstract/21,52\">",
"     21,52",
"    </a>",
"    ]. A prospective multicenter study is ongoing to assess the efficacy of an N-acetylcysteine, tigecycline, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    combination lock in a larger adult hemodialysis population [",
"    <a class=\"abstract\" href=\"UTD.htm?2/4/2121/abstract/61\">",
"     61",
"    </a>",
"    ]. Until further data are available, we do not recommend use of N-acetylcysteine in antibiotic lock solutions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3711289\">",
"    <span class=\"h2\">",
"     Ethanol lock solutions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lock solutions containing ethanol alone have demonstrated comparable efficacy in small observational studies, particularly in pediatric populations [",
"    <a class=\"abstract\" href=\"UTD.htm?2/4/2121/abstract/62-65\">",
"     62-65",
"    </a>",
"    ]. However, these results are too preliminary to support recommendation of this lock type.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21997953\">",
"    <span class=\"h1\">",
"     ADMINISTRATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antibiotic lock therapy (ALT) should only be used in conjunction with systemic antibiotics.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13928516\">",
"    <span class=\"h2\">",
"     Instillation and dwell time",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antibiotic lock solutions should be prepared immediately before instillation into the catheter lumen by mixing the appropriate solutions used for systemic administration of antibiotics in a single syringe. Ideally, antibiotic lock solutions should be prepared by pharmacists. However, if this is not feasible in local outpatient settings, such as community-based, free-standing dialysis units, nurses who prepare these solutions should be trained in safe injection practices as they relate to use of multidose or single-use vials and instructed in the correct calculation of dosages.",
"   </p>",
"   <p>",
"    Dwell times will depend on the available time that the catheter is not otherwise in use, and in studies have ranged from 4 to 72 hours. For hemodialysis catheters, the ALT can dwell in the catheter during the interval between sessions, up to 72 hours. Otherwise, dwell times should generally not exceed 48 hours, as antibiotic concentrations in the distal lumen of the catheter can decrease to subtherapeutic levels over time [",
"    <a class=\"abstract\" href=\"UTD.htm?2/4/2121/abstract/66\">",
"     66",
"    </a>",
"    ]. At the end of the dwell time or when the catheter is required for alternate use, the ALT should be withdrawn to avoid exposure to high concentrations of the antibiotic and anticoagulant.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21997765\">",
"    <span class=\"h2\">",
"     Duration of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although some studies have reported success with shorter courses of ALT therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?2/4/2121/abstract/28,31\">",
"     28,31",
"    </a>",
"    ], we use ALT in conjunction with and for the same duration as systemic antibiotics (usually 7 to 14 days, depending on the organism) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/4/2121/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13928508\">",
"    <span class=\"h1\">",
"     ADVERSE EFFECTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Potential adverse effects of antibiotic lock therapy (ALT) are fungal superinfection, systemic toxicities of antibiotics or anticoagulants included in lock solutions, and emergence of antibiotic resistance with failure.",
"   </p>",
"   <p>",
"    Secondary candidemia has been reported in patients receiving ALT along with broad-spectrum systemic antibiotics or concomitant immunosuppressants [",
"    <a class=\"abstract\" href=\"UTD.htm?2/4/2121/abstract/3,16,19,37\">",
"     3,16,19,37",
"    </a>",
"    ]. In particular, a high proportion of secondary candidal bloodstream infections was observed with ALT for enterococcal catheter-related bloodstream infection (CRBSI) (42 percent) treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/10/36000?source=see_link\">",
"     gentamicin",
"    </a>",
"    in one study [",
"    <a class=\"abstract\" href=\"UTD.htm?2/4/2121/abstract/16\">",
"     16",
"    </a>",
"    ]; however, subsequent studies that did not use gentamicin in the ALT regimen described lower rates of candidemia (2 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/4/2121/abstract/19,22\">",
"     19,22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Sensorineural hearing loss has been reported with prolonged use of an amikacin-",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    lock to prevent catheter infection, but there are no reports of major toxicities or antibiotic resistance with short courses of ALT used to treat CRBSI [",
"    <a class=\"abstract\" href=\"UTD.htm?2/4/2121/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13928500\">",
"    <span class=\"h1\">",
"     MONITORING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients must be monitored closely during and after antibiotic lock therapy (ALT) for treatment of catheter-related bloodstream infection to detect failure of therapy, signs of complications, or relapse. Infected catheters should be removed in patients who remain febrile 48 to 72 hours after initiating ALT, who have persistently positive blood cultures 72 hours after initiating ALT, or who have signs of sepsis, hemodynamic instability, or metastatic infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/20/7498?source=see_link&amp;anchor=H21#H21\">",
"     \"Treatment of intravascular catheter-related infections\", section on 'Follow-up'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/8/29834?source=see_link&amp;anchor=H19#H19\">",
"     \"Tunneled, cuffed hemodialysis catheter-related bacteremia\", section on 'Catheter management'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4202387\">",
"    <span class=\"h1\">",
"     PROPHYLAXIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevention of catheter-related infections, including the use of antibiotic lock therapy prophylactically, is reviewed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/53/31578?source=see_link&amp;anchor=H16#H16\">",
"     \"Prevention of intravascular catheter-related infections\", section on 'Antibiotic locks'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H50341376\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Antibiotic lock therapy (ALT) involves instillation of a concentrated antibiotic solution into the catheter lumen with the intention of achieving a drug level high enough to kill sessile bacteria within the biofilm of the catheter. Anticoagulants are often included in the solution and are thought to facilitate antibiotic penetration into microbial biofilm. (See",
"      <a class=\"local\" href=\"#H50341281\">",
"       'Rationale for use'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For clinically stable children and adults with infections of long-term tunneled central venous catheters and ports due to coagulase-negative staphylococci, gram-negative rods, and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"       vancomycin",
"      </a>",
"      -sensitive enterococci in whom a decision is made to salvage the catheter, we suggest ALT in conjunction with systemic antibiotics rather than systemic antibiotics alone (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H13928254\">",
"       'Indications and contraindications'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H50341318\">",
"       'Efficacy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Catheter management options for catheter-related bloodstream infections (CRBSI) include removal, salvage, and exchange over a guidewire. Catheter salvage should not be attempted in the following circumstances (see",
"      <a class=\"local\" href=\"#H13928254\">",
"       'Indications and contraindications'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/20/7498?source=see_link&amp;anchor=H3#H3\">",
"       \"Treatment of intravascular catheter-related infections\", section on 'Catheter management'",
"      </a>",
"      ):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Complicated CRBSI",
"     </li>",
"     <li>",
"      Severe sepsis or hemodynamic instability",
"     </li>",
"     <li>",
"      Persistent bacteremia despite 72 hours of appropriate antibiotic therapy",
"     </li>",
"     <li>",
"      Infections caused by S. aureus, P. aeruginosa, fungi, mycobacteria, Bacillus species, Micrococcus species, or Propionibacteria",
"     </li>",
"     <li>",
"      Tunnel infections, port abscesses, or exit site infections",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/2/4136?source=see_link\">",
"       Cefazolin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"       vancomycin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/0/17415?source=see_link\">",
"       ceftazidime",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/10/36000?source=see_link\">",
"       gentamicin",
"      </a>",
"      are commonly used in ALT and are stable in solution with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      over a prolonged period of time (",
"      <a class=\"graphic graphic_table graphicRef83938 \" href=\"UTD.htm?0/21/349\">",
"       table 1",
"      </a>",
"      ). Specific antibiotic selection for ALT should be guided by culture and susceptibility results when available. We favor a dose in which the final antibiotic concentration exceeds the minimum inhibitory concentration (MIC) of the organism by at least 1000-fold. (See",
"      <a class=\"local\" href=\"#H112483117\">",
"       'Antibiotic lock solution choice'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients receiving ALT, we typically include",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      in the antibiotic lock solution unless there is a contraindication to heparin (eg, heparin-induced thrombocytopenia). For patients with contraindications to heparin, only antibiotics that have been shown be stable and effective when used alone should be administered (",
"      <a class=\"graphic graphic_table graphicRef83939 \" href=\"UTD.htm?29/45/30429\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H112483117\">",
"       'Antibiotic lock solution choice'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Antibiotic lock solutions should be administered in an amount sufficient to fill and dwell in the catheter lumen when the catheter is not in use. Depending on the need for access, dwell times can range from four to six hours to three days, after which the solution should be withdrawn and discarded. (See",
"      <a class=\"local\" href=\"#H13928516\">",
"       'Instillation and dwell time'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Fungal superinfection, systemic toxicities of antibiotics or anticoagulants included in lock solutions, and emergence of antibiotic resistance with failure are potential but not frequently reported adverse effects. (See",
"      <a class=\"local\" href=\"#H13928508\">",
"       'Adverse effects'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Infected catheters should be removed in patients who remain febrile 48 to 72 hours after initiating ALT, who have persistently positive blood cultures 72 hours after initiating ALT, or who have signs of sepsis, hemodynamic instability, or metastatic infection. (See",
"      <a class=\"local\" href=\"#H13928500\">",
"       'Monitoring'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/4/2121/abstract/1\">",
"      Maki DG, Kluger DM, Crnich CJ. The risk of bloodstream infection in adults with different intravascular devices: a systematic review of 200 published prospective studies. Mayo Clin Proc 2006; 81:1159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/4/2121/abstract/2\">",
"      O'Grady NP, Alexander M, Burns LA, et al. Guidelines for the prevention of intravascular catheter-related infections. Clin Infect Dis 2011; 52:e162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/4/2121/abstract/3\">",
"      Messing B, Peitra-Cohen S, Debure A, et al. Antibiotic-lock technique: a new approach to optimal therapy for catheter-related sepsis in home-parenteral nutrition patients. JPEN J Parenter Enteral Nutr 1988; 12:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/4/2121/abstract/4\">",
"      Messing B. Catheter-sepsis during home parenteral nutrition: use of the antibiotic-lock technique. Nutrition 1998; 14:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/4/2121/abstract/5\">",
"      Raad I, Davis S, Khan A, et al. Impact of central venous catheter removal on the recurrence of catheter-related coagulase-negative staphylococcal bacteremia. Infect Control Hosp Epidemiol 1992; 13:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/4/2121/abstract/6\">",
"      Gaillard JL, Merlino R, Pajot N, et al. Conventional and nonconventional modes of vancomycin administration to decontaminate the internal surface of catheters colonized with coagulase-negative staphylococci. JPEN J Parenter Enteral Nutr 1990; 14:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/4/2121/abstract/7\">",
"      Pascual A, Ramirez de Arellano E, Mart&iacute;nez Mart&iacute;nez L, Perea EJ. Effect of polyurethane catheters and bacterial biofilms on the in-vitro activity of antimicrobials against Staphylococcus epidermidis. J Hosp Infect 1993; 24:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/4/2121/abstract/8\">",
"      Raad I, Costerton W, Sabharwal U, et al. Ultrastructural analysis of indwelling vascular catheters: a quantitative relationship between luminal colonization and duration of placement. J Infect Dis 1993; 168:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/4/2121/abstract/9\">",
"      Carratal&agrave; J. The antibiotic-lock technique for therapy of 'highly needed' infected catheters. Clin Microbiol Infect 2002; 8:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/4/2121/abstract/10\">",
"      Saxena AK, Panhotra BR, Naguib M. Sudden irreversible sensory-neural hearing loss in a patient with diabetes receiving amikacin as an antibiotic-heparin lock. Pharmacotherapy 2002; 22:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/4/2121/abstract/11\">",
"      Karaaslan H, Peyronnet P, Benevent D, et al. Risk of heparin lock-related bleeding when using indwelling venous catheter in haemodialysis. Nephrol Dial Transplant 2001; 16:2072.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/4/2121/abstract/12\">",
"      Mermel LA, Allon M, Bouza E, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 49:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/4/2121/abstract/13\">",
"      Fowler VG Jr, Justice A, Moore C, et al. Risk factors for hematogenous complications of intravascular catheter-associated Staphylococcus aureus bacteremia. Clin Infect Dis 2005; 40:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/4/2121/abstract/14\">",
"      Kassar R, Hachem R, Jiang Y, et al. Management of Bacillus bacteremia: the need for catheter removal. Medicine (Baltimore) 2009; 88:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/4/2121/abstract/15\">",
"      Ramos ER, Hachem R, Youssef S, et al. The crucial role of catheters in micrococcal bloodstream infections in cancer patients. Infect Control Hosp Epidemiol 2009; 30:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/4/2121/abstract/16\">",
"      Krishnasami Z, Carlton D, Bimbo L, et al. Management of hemodialysis catheter-related bacteremia with an adjunctive antibiotic lock solution. Kidney Int 2002; 61:1136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/4/2121/abstract/17\">",
"      Capdevila JA, Segarra A, Planes AM, et al. Successful treatment of haemodialysis catheter-related sepsis without catheter removal. Nephrol Dial Transplant 1993; 8:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/4/2121/abstract/18\">",
"      Boorgu R, Dubrow AJ, Levin NW, et al. Adjunctive antibiotic/anticoagulant lock therapy in the treatment of bacteremia associated with the use of a subcutaneously implanted hemodialysis access device. ASAIO J 2000; 46:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/4/2121/abstract/19\">",
"      Poole CV, Carlton D, Bimbo L, Allon M. Treatment of catheter-related bacteraemia with an antibiotic lock protocol: effect of bacterial pathogen. Nephrol Dial Transplant 2004; 19:1237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/4/2121/abstract/20\">",
"      Maya ID, Carlton D, Estrada E, Allon M. Treatment of dialysis catheter-related Staphylococcus aureus bacteremia with an antibiotic lock: a quality improvement report. Am J Kidney Dis 2007; 50:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/4/2121/abstract/21\">",
"      Aslam S, Trautner BW, Ramanathan V, Darouiche RO. Pilot trial of N-acetylcysteine and tigecycline as a catheter-lock solution for treatment of hemodialysis catheter-associated bacteremia. Infect Control Hosp Epidemiol 2008; 29:894.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/4/2121/abstract/22\">",
"      Peterson WJ, Maya ID, Carlton D, et al. Treatment of dialysis catheter-related Enterococcus bacteremia with an antibiotic lock: a quality improvement report. Am J Kidney Dis 2009; 53:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/4/2121/abstract/23\">",
"      Messing B, Man F, Colimon R, et al. Antibiotic-lock technique is an effective treatment of bacterial catheter-related sepsis during parenteral nutrition. Clin Nutr 1990; 9:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/4/2121/abstract/24\">",
"      Williams N, Carlson GL, Scott NA, Irving MH. Incidence and management of catheter-related sepsis in patients receiving home parenteral nutrition. Br J Surg 1994; 81:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/4/2121/abstract/25\">",
"      Krzywda EA, Andris DA, Edmiston CE Jr, Quebbeman EJ. Treatment of Hickman catheter sepsis using antibiotic lock technique. Infect Control Hosp Epidemiol 1995; 16:596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/4/2121/abstract/26\">",
"      Benoit JL, Carandang G, Sitrin M, Arnow PM. Intraluminal antibiotic treatment of central venous catheter infections in patients receiving parenteral nutrition at home. Clin Infect Dis 1995; 21:1286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/4/2121/abstract/27\">",
"      Reimund JM, Arondel Y, Finck G, et al. Catheter-related infection in patients on home parenteral nutrition: results of a prospective survey. Clin Nutr 2002; 21:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/4/2121/abstract/28\">",
"      Viale P, Pagani L, Petrosillo N, et al. Antibiotic lock-technique for the treatment of catheter-related bloodstream infections. J Chemother 2003; 15:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/4/2121/abstract/29\">",
"      S&aacute;nchez-Mu&ntilde;oz A, Aguado JM, L&oacute;pez-Mart&iacute;n A, et al. Usefulness of antibiotic-lock technique in management of oncology patients with uncomplicated bacteremia related to tunneled catheters. Eur J Clin Microbiol Infect Dis 2005; 24:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/4/2121/abstract/30\">",
"      Rijnders BJ, Van Wijngaerden E, Vandecasteele SJ, et al. Treatment of long-term intravascular catheter-related bacteraemia with antibiotic lock: randomized, placebo-controlled trial. J Antimicrob Chemother 2005; 55:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/4/2121/abstract/31\">",
"      Fernandez-Hidalgo N, Almirante B, Calleja R, et al. Antibiotic-lock therapy for long-term intravascular catheter-related bacteraemia: results of an open, non-comparative study. J Antimicrob Chemother 2006; 57:1172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/4/2121/abstract/32\">",
"      Fort&uacute;n J, Grill F, Mart&iacute;n-D&aacute;vila P, et al. Treatment of long-term intravascular catheter-related bacteraemia with antibiotic-lock therapy. J Antimicrob Chemother 2006; 58:816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/4/2121/abstract/33\">",
"      Rao JS, O'Meara A, Harvey T, Breatnach F. A new approach to the management of Broviac catheter infection. J Hosp Infect 1992; 22:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/4/2121/abstract/34\">",
"      Johnson DC, Johnson FL, Goldman S. Preliminary results treating persistent central venous catheter infections with the antibiotic lock technique in pediatric patients. Pediatr Infect Dis J 1994; 13:930.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/4/2121/abstract/35\">",
"      Megged O, Shalit I, Yaniv I, et al. Outcome of antibiotic lock technique for persistent central venous catheter-associated coagulase-negative Staphylococcus bacteremia in children. Eur J Clin Microbiol Infect Dis 2010; 29:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/4/2121/abstract/36\">",
"      Longuet P, Douard MC, Arlet G, et al. Venous access port--related bacteremia in patients with acquired immunodeficiency syndrome or cancer: the reservoir as a diagnostic and therapeutic tool. Clin Infect Dis 2001; 32:1776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/4/2121/abstract/37\">",
"      Del Pozo JL, Alonso M, Serrera A, et al. Effectiveness of the antibiotic lock therapy for the treatment of port-related enterococci, Gram-negative, or Gram-positive bacilli bloodstream infections. Diagn Microbiol Infect Dis 2009; 63:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/4/2121/abstract/38\">",
"      Del Pozo JL, Garc&iacute;a Cenoz M, Hern&aacute;ez S, et al. Effectiveness of teicoplanin versus vancomycin lock therapy in the treatment of port-related coagulase-negative staphylococci bacteraemia: a prospective case-series analysis. Int J Antimicrob Agents 2009; 34:482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/4/2121/abstract/39\">",
"      Funalleras G, Fern&aacute;ndez-Hidalgo N, Borrego A, et al. Effectiveness of antibiotic-lock therapy for long-term catheter-related bacteremia due to Gram-negative bacilli: a prospective observational study. Clin Infect Dis 2011; 53:e129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/4/2121/abstract/40\">",
"      O'Horo JC, Silva GL, Safdar N. Anti-infective locks for treatment of central line-associated bloodstream infection: a systematic review and meta-analysis. Am J Nephrol 2011; 34:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/4/2121/abstract/41\">",
"      Viale P, Stefani S. Vascular catheter-associated infections: a microbiological and therapeutic update. J Chemother 2006; 18:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/4/2121/abstract/42\">",
"      Henrickson KJ, Powell KR, Schwartz CL. A dilute solution of vancomycin and heparin retains antibacterial and anticoagulant activities. J Infect Dis 1988; 157:600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/4/2121/abstract/43\">",
"      Henrickson KJ, Dunne WM Jr. Modification of central venous catheter flush solution improves in vitro antimicrobial activity. J Infect Dis 1992; 166:944.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/4/2121/abstract/44\">",
"      Bookstaver PB, Williamson JC, Tucker BK, et al. Activity of novel antibiotic lock solutions in a model against isolates of catheter-related bloodstream infections. Ann Pharmacother 2009; 43:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/4/2121/abstract/45\">",
"      Vercaigne LM, Sitar DS, Penner SB, et al. Antibiotic-heparin lock: in vitro antibiotic stability combined with heparin in a central venous catheter. Pharmacotherapy 2000; 20:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/4/2121/abstract/46\">",
"      Vercaigne LM, Zelenitsky SA, Findlay I, et al. An in vitro evaluation of the antibiotic/heparin lock to sterilize central venous haemodialysis catheters. J Antimicrob Chemother 2002; 49:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/4/2121/abstract/47\">",
"      LaPlante KL, Mermel LA. In vitro activity of daptomycin and vancomycin lock solutions on staphylococcal biofilms in a central venous catheter model. Nephrol Dial Transplant 2007; 22:2239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/4/2121/abstract/48\">",
"      Andris DA, Krzywda EA, Edmiston CE, et al. Elimination of intraluminal colonization by antibiotic lock in silicone vascular catheters. Nutrition 1998; 14:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/4/2121/abstract/49\">",
"      Lee JY, Ko KS, Peck KR, et al. In vitro evaluation of the antibiotic lock technique (ALT) for the treatment of catheter-related infections caused by staphylococci. J Antimicrob Chemother 2006; 57:1110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/4/2121/abstract/50\">",
"      Lee MY, Ko KS, Song JH, Peck KR. In vitro effectiveness of the antibiotic lock technique (ALT) for the treatment of catheter-related infections by Pseudomonas aeruginosa and Klebsiella pneumoniae. J Antimicrob Chemother 2007; 60:782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/4/2121/abstract/51\">",
"      Raad I, Hanna H, Jiang Y, et al. Comparative activities of daptomycin, linezolid, and tigecycline against catheter-related methicillin-resistant Staphylococcus bacteremic isolates embedded in biofilm. Antimicrob Agents Chemother 2007; 51:1656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/4/2121/abstract/52\">",
"      Aslam S, Trautner BW, Ramanathan V, Darouiche RO. Combination of tigecycline and N-acetylcysteine reduces biofilm-embedded bacteria on vascular catheters. Antimicrob Agents Chemother 2007; 51:1556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/4/2121/abstract/53\">",
"      von Eiff C, Jansen B, Kohnen W, Becker K. Infections associated with medical devices: pathogenesis, management and prophylaxis. Drugs 2005; 65:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/4/2121/abstract/54\">",
"      Kim EY, Saunders P, Yousefzadeh N. Usefulness of anti-infective lock solutions for catheter-related bloodstream infections. Mt Sinai J Med 2010; 77:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/4/2121/abstract/55\">",
"      Anthony TU, Rubin LG. Stability of antibiotics used for antibiotic-lock treatment of infections of implantable venous devices (ports). Antimicrob Agents Chemother 1999; 43:2074.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/4/2121/abstract/56\">",
"      Droste JC, Jeraj HA, MacDonald A, Farrington K. Stability and in vitro efficacy of antibiotic-heparin lock solutions potentially useful for treatment of central venous catheter-related sepsis. J Antimicrob Chemother 2003; 51:849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/4/2121/abstract/57\">",
"      Robinson JL, Tawfik G, Saxinger L, et al. Stability of heparin and physical compatibility of heparin/antibiotic solutions in concentrations appropriate for antibiotic lock therapy. J Antimicrob Chemother 2005; 56:951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/4/2121/abstract/58\">",
"      Shanks RM, Donegan NP, Graber ML, et al. Heparin stimulates Staphylococcus aureus biofilm formation. Infect Immun 2005; 73:4596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/4/2121/abstract/59\">",
"      Shanks RM, Sargent JL, Martinez RM, et al. Catheter lock solutions influence staphylococcal biofilm formation on abiotic surfaces. Nephrol Dial Transplant 2006; 21:2247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/4/2121/abstract/60\">",
"      Sauer K, Steczko J, Ash SR. Effect of a solution containing citrate/Methylene Blue/parabens on Staphylococcus aureus bacteria and biofilm, and comparison with various heparin solutions. J Antimicrob Chemother 2009; 63:937.",
"     </a>",
"    </li>",
"    <li>",
"     file://clinicaltrials.gov/ct2/show/NCT00614679?term=antibiotic+lock+and+tigecycline&amp;rank=1 (Accessed on September 09, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/4/2121/abstract/62\">",
"      Onland W, Shin CE, Fustar S, et al. Ethanol-lock technique for persistent bacteremia of long-term intravascular devices in pediatric patients. Arch Pediatr Adolesc Med 2006; 160:1049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/4/2121/abstract/63\">",
"      Broom J, Woods M, Allworth A, et al. Ethanol lock therapy to treat tunnelled central venous catheter-associated blood stream infections: results from a prospective trial. Scand J Infect Dis 2008; 40:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/4/2121/abstract/64\">",
"      Dannenberg C, Bierbach U, Rothe A, et al. Ethanol-lock technique in the treatment of bloodstream infections in pediatric oncology patients with broviac catheter. J Pediatr Hematol Oncol 2003; 25:616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/4/2121/abstract/65\">",
"      Valentine KM. Ethanol lock therapy for catheter-associated blood stream infections in a pediatric intensive care unit. Pediatr Crit Care Med 2011; 12:e292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/4/2121/abstract/66\">",
"      Soriano A, Bregada E, Marqu&eacute;s JM, et al. Decreasing gradient of antibiotic concentration in the lumen of catheters locked with vancomycin. Eur J Clin Microbiol Infect Dis 2007; 26:659.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13982 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.25.216.6-A93D27A9D4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_4_2121=[""].join("\n");
var outline_f2_4_2121=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H50341376\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H50341274\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H50341281\">",
"      RATIONALE FOR USE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13928254\">",
"      INDICATIONS AND CONTRAINDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H50341318\">",
"      EFFICACY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H50341333\">",
"      Hemodialysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H50341340\">",
"      Total parenteral nutrition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H50341354\">",
"      Children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H50341361\">",
"      Port-related CRBSI",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H112483117\">",
"      ANTIBIOTIC LOCK SOLUTION CHOICE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4202042\">",
"      Antibiotic",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21997797\">",
"      Anticoagulant",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21998020\">",
"      Other solution additives",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3711289\">",
"      Ethanol lock solutions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21997953\">",
"      ADMINISTRATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13928516\">",
"      Instillation and dwell time",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21997765\">",
"      Duration of therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13928508\">",
"      ADVERSE EFFECTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13928500\">",
"      MONITORING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4202387\">",
"      PROPHYLAXIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H50341376\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/13982\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/13982|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/21/349\" title=\"table 1\">",
"      Common antibiotic and anticoagulant lock solutions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?29/45/30429\" title=\"table 2\">",
"      Antibiotic lock solutions without anticoagulant",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/23/375?source=related_link\">",
"      Diagnosis of intravascular catheter-related infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/37/37464?source=related_link\">",
"      Epidemiology, pathogenesis, and microbiology of intravascular catheter infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/53/31578?source=related_link\">",
"      Prevention of intravascular catheter-related infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/20/7498?source=related_link\">",
"      Treatment of intravascular catheter-related infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/8/29834?source=related_link\">",
"      Tunneled, cuffed hemodialysis catheter-related bacteremia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_4_2122="Cerebral arterial circulation";
var content_f2_4_2122=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F51410&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F51410&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 595px\">",
"   <div class=\"ttl\">",
"    Anatomy of the cerebral arterial circulation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 575px; height: 661px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Frontal view of the carotid arteries, vertebral arteries and intracranial vessels and their communication with each other via the Circle of Willis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Uflacker R. Atlas Of Vascular Anatomy: An Angiographic Approach, Second Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2006. Copyright &copy; 2006 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_4_2122=[""].join("\n");
var outline_f2_4_2122=null;
var title_f2_4_2123="Endotracheal tube size formula";
var content_f2_4_2123=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F72932&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F72932&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Age-based formula for selecting endotracheal tube size (internal diameter in mm)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Uncuffed tube",
"       </td>",
"       <td class=\"subtitle1\">",
"        Cuffed tube",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4 + (age in years/4)",
"       </td>",
"       <td>",
"        3.5 + (age in years/4)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Additional tubes one size larger and one size smaller than calculated should also be available.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Formula for cuffed tubes from:",
"     <br>",
"      Wheeler, M, Cot&eacute;, CJ, Todres, ID. The pediatric airway. In: A Practice of Anesthesia for Infants and Children, 4th ed, Cot&eacute;, C, Lerman, J, Todres, ID (Eds), Saunders-Elsevier, Philadelphia 2009. p.237.",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_4_2123=[""].join("\n");
var outline_f2_4_2123=null;
var title_f2_4_2124="Causes postinf GN";
var content_f2_4_2124=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F76710&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F76710&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Bacterial and viral agents associated with post-infectious glomerulonephritis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Bacterial infections",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Skin or throat (Streptococcus group A)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Endocarditis (Staphylococcus aureus, Streptococcus viridans)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Visceral abcess (Staphylococcus aureus, E. coli, Pseudomonas, Proteus mirabilis)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Shunt nephritis (Staphylococcus aureus, Staphylococcus albus, Streptococcus viridans)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pneumonia (Diplococcus pneumoniae, Mycoplasma)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Typhoid fever (Salmonella typhi)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Viral infections",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Epstein Barr virus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Parvovirus B19",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Varicella",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cytomegalovirus infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Coxsackie",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rubella",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mumps",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hepatitis B",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Parasitic infections",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Schistosoma mansoni",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Plasmodium falciparum",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Toxoplasma gondii",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Filaria",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Original figure modified for this publication. Reproduced with permission from: Niaudet P. Nephritic Syndrome. In: Comprehensive Pediatric Nephrology, Geary DF, Schaefer F (Eds), Mosby, Philadelphia 2008. Illustration used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_4_2124=[""].join("\n");
var outline_f2_4_2124=null;
var title_f2_4_2125="Provocative elbow testing";
var content_f2_4_2125=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F60590&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F60590&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Provocative testing of the elbow",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Test",
"       </td>",
"       <td class=\"subtitle1\">",
"        Positive Maneuver",
"       </td>",
"       <td class=\"subtitle1\">",
"        Diagnosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Valgus testing of medial complex",
"       </td>",
"       <td>",
"        Elbow at 15&deg; flexion",
"       </td>",
"       <td rowspan=\"2\">",
"        Ulnar collateral ligament insufficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Shoulder externally rotated",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Moving valgus stress test",
"       </td>",
"       <td>",
"        With the shoulder abducted to 90",
"        <sup>",
"         o",
"        </sup>",
"        and fully externally rotated and the elbow fully flexed, valgus force to the elbow during its extension causes pain at 70",
"        <sup>",
"         o",
"        </sup>",
"        to 120",
"        <sup>",
"         o",
"        </sup>",
"        of elbow flexion",
"       </td>",
"       <td>",
"        Ulnar collateral ligament insufficiency&nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Varus testing of medial complex",
"       </td>",
"       <td>",
"        Elbow at 15&deg; flexion",
"       </td>",
"       <td rowspan=\"2\">",
"        Lateral collateral ligament insufficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Shoulder internally rotated",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tinel sign",
"       </td>",
"       <td>",
"        Reproduction of pain/numbness in the 4th and 5th fingers with tapping on the groove between medial epicondyle and the olecranon process with the elbow flexed at 90&deg; and the arm externally rotatied",
"       </td>",
"       <td>",
"        Ulnar neuritis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"3\">",
"        Median compressive neuropathies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Pronator compression",
"       </td>",
"       <td class=\"sublist_other\">",
"        Reproduction of pain and altered sensation by direct pressure over the pronator teres during resisted pronation",
"       </td>",
"       <td class=\"sublist_other\">",
"        Pronator teres syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Prolonged resisted pronation",
"       </td>",
"       <td class=\"sublist_other\">",
"        Digital pressure on proximal lateral edge of pronator teres for 30 sec with resisted forearm supination",
"       </td>",
"       <td class=\"sublist_other\">",
"        Lacertus fibrosis syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        OK sign",
"       </td>",
"       <td class=\"sublist_other\">",
"        Decreased strength or pincer grasp",
"       </td>",
"       <td class=\"sublist_other\">",
"        Anterior interosseous syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Long finger PIP flexion",
"       </td>",
"       <td class=\"sublist_other\">",
"        Resisted PIP flexion of the long finger",
"       </td>",
"       <td class=\"sublist_other\">",
"        Flexor digitorum superficialis syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"3\">",
"        Radial compressive neuropathies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Superficial radial nerve tenderness",
"       </td>",
"       <td class=\"sublist_other\">",
"        Superficial radial nerve tenderness over extensors 8 cm distal to lateral epicondyle",
"       </td>",
"       <td class=\"sublist_other\">",
"        Superficial radial nerve",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Long finger extension",
"       </td>",
"       <td class=\"sublist_other\">",
"        Pain with resisted long finger flexion at the meta-carpophalangeal joint with wrist in 30&deg; flexion and fingers extended",
"       </td>",
"       <td class=\"sublist_other\">",
"        Superficial radial nerve",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Radial deviation",
"       </td>",
"       <td class=\"sublist_other\">",
"        Radial deviation of the wrist with active wrist extension",
"       </td>",
"       <td class=\"sublist_other\">",
"        Posterior interosseous syndrome",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_4_2125=[""].join("\n");
var outline_f2_4_2125=null;
var title_f2_4_2126="Contents: Urticaria and angioedema";
var content_f2_4_2126=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?1/34/1568\">",
"       Family Medicine and General Practice",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Urticaria and angioedema",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Urticaria and angioedema",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Angioedema",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/37/37465\">",
"           ACE inhibitor-induced angioedema",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/12/26824\">",
"           Acquired C1 inhibitor deficiency: Clinical manifestations, epidemiology, pathogenesis, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/20/25927\">",
"           Acquired C1 inhibitor deficiency: Management and prognosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/17/15641\">",
"           An overview of angioedema: Clinical features, diagnosis, and management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/31/38391\">",
"           An overview of angioedema: Pathogenesis and causes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/52/19272\">",
"           Hereditary angioedema: Epidemiology, clinical manifestations, exacerbating factors, and prognosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/4/33864\">",
"           Hereditary angioedema: Pathogenesis and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/61/29658\">",
"           Hereditary angioedema: Prevention of attacks",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/55/33657\">",
"           Hereditary angioedema: Treatment of acute attacks",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/61/5080\">",
"           Type III hereditary angioedema",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Urticaria",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/19/30010\">",
"           Chronic urticaria: Clinical manifestations, diagnosis, pathogenesis, and natural history",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/7/117\">",
"           Chronic urticaria: Standard management and patient education",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/53/30554\">",
"           Chronic urticaria: Treatment of refractory symptoms",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/22/15721\">",
"           Cold urticaria",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/24/21898\">",
"           New onset urticaria",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/5/24666\">",
"           Physical urticarias",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/60/32714\">",
"           Urticarial vasculitis",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-0C7A1AAADF-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f2_4_2126=[""].join("\n");
var outline_f2_4_2126=null;
var title_f2_4_2127="IADPSG protocol for evaluation of diabetes in pregnancy";
var content_f2_4_2127=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F64477&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F64477&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    IADPSG protocol for the evaluation of diabetes in pregnancy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 424px; height: 428px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     IADPSG: International Association of Diabetes and Pregnancy Study Group; A1C: glycosylated hemoglobin or hemoglobin A1C; FBG: fasting blood glucose; BG: blood glucose; GTT: glucose tolerance test; GDM: gestational diabetes mellitus.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: International Association of Diabetes and Pregnancy Study Groups Consensus Panel. International Association of Diabetes and Pregnancy Study Groups recommendations on the diagnosis and classification of hyperglycemia in pregnancy. Diabetes Care 2010; 33:676.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_4_2127=[""].join("\n");
var outline_f2_4_2127=null;
